1. Introduction

ijms

International Journal of Molecular Sciences

Int. J. Mol. Sci.

1422-0067

Molecular Diversity Preservation International (MDPI)

10.3390/ijms13079298

ijms-13-09298

Review

The Immunomodulatory and Neuroprotective Effects of Mesenchymal Stem Cells (MSCs) in Experimental Autoimmune Encephalomyelitis (EAE): A Model of Multiple Sclerosis (MS)

Al Jumah

Mohammed A.

Abumaree

Mohamed H.

* College of medicine, King Saud Bin Abdulaziz University for Health Sciences, King Abdullah International Medical Research Center, King Abdulaziz Medical City, National Guard Health Affairs, P.O. Box 22490, Riyadh 11426, Mail Code 1515, Saudi Arabia; E-Mail: jumahm@ngha.med.sa

*Author to whom correspondence should be addressed; E-Mail: abumareem@ksau-hs.edu.sa; Tel.: +966-1-2520088 (ext. 47180); Fax: +966-1-2520088 (ext. 47120).

2012

24 07 2012

13 7 9298 9331 18 05 2012 11 07 2012 11 07 2012

2012

This article is an open-access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).

Mesenchymal stem cells (MSCs) are multipotent cells that differentiate into the mesenchymal lineages of adipocytes, osteocytes and chondrocytes. MSCs can also transdifferentiate and thereby cross lineage barriers, differentiating for example into neurons under certain experimental conditions. MSCs have anti-proliferative, anti-inflammatory and anti-apoptotic effects on neurons. Therefore, MSCs were tested in experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis (MS), for their effectiveness in modulating the pathogenic process in EAE to develop effective therapies for MS. The data in the literature have shown that MSCs can inhibit the functions of autoreactive T cells in EAE and that this immunomodulation can be neuroprotective. In addition, MSCs can rescue neural cells via a mechanism that is mediated by soluble factors, which provide a suitable environment for neuron regeneration, remyelination and cerebral blood flow improvement. In this review, we discuss the effectiveness of MSCs in modulating the immunopathogenic process and in providing neuroprotection in EAE.

mesenchymal stem cells (MSC) experimental autoimmune encephalomyelitis (EAE) central nervous system (CNS) neurons microglia oligodendrocytes neuroprotection

1. Introduction

Multiple sclerosis (MS) is a chronic, progressive inflammatory disorder of the central nervous system (CNS). It is characterized by myelin loss, various degrees of axonal pathology, and progressive neurological dysfunction [1]. The associated inflammatory plaque is the pathological hallmark of MS [2]. Experimental autoimmune encephalomyelitis (EAE) is the best-characterized animal model of MS [3]. The finding of inflammatory cells and their secreted molecules in the brain lesions of MS patients and of animals with EAE has supported the widely accepted notion that MS is mediated by pathogenic T cells, which react with myelin antigens, resulting in a larger degeneration of surrounding neurons [4]. These autoreactive T cells then migrate and cross the blood-brain barrier (BBB) to destroy the central neurons and their myelin sheaths as well as their axons.

The exact etiology of MS remains unknown. However, there are three key hypotheses that may explain the causes underlying MS, namely an immune response against the CNS, pathogen trigger and oligodendrocyte degeneration. In addition, genetic factors contribute to MS. Although the pathogenesis of MS is poorly understood, increasing evidence suggests that genetic and environmental factors may both contribute to the development of the disease [5]. Typically, MS affects young adults between 20 and 40 years of age [4,6]. MS shows a strong gender preference, with approximately 70 to 75% of all people with MS being female [4,6]. The incidence and prevalence of MS vary throughout the world, with at least one to two million individuals affected worldwide.

The key morphological characteristic of MS is the demyelination of nerve axons, which blocks or slows signal conduction at the site of demyelination [4,7]. MS patients suffer from a number of neurological symptoms, such as visual problems, changes in sensation, weakness, spasticity, acute/chronic pain, fatigue, depression and paralysis. Neurological symptoms develop when conduction blockade occurs concurrently in a considerable percentage of fibers within a particular neural pathway [7]. During clinical recovery, the inflammation and edema in the CNS resolve, and it is suggested that the restoration of CNS conductivity results from glial ensheathment and remyelination. In contrast, axonal loss is irreversible and may be the basis of neurological dysfunction in chronic MS.

Traditionally, there are four clinical forms of MS: relapsing-remitting MS (RRMS), secondary progressive MS (SPMS), primary progressive MS (PPMS), and progressive relapsing MS (PR). There is also another form of MS known as clinically isolated syndromes (CIS). These patients present with a single attack of the disease but are not yet diagnosed with MS. The most common form of MS is RRMS, which is associated with acute inflammatory episodes and a reduction in neurological functions [4]. Patients may experience some recovery between relapses, but 80% of RRMS patients progress to SPMS, which is associated with gradual loss of neurological functions and ascending paralysis [4].

In MS, remyelination and restoration of neuronal functions can be achieved by promoting endogenous mechanisms of neuronal repair or by transplanting exogenous myelinating cells [8]. However, long-term neuronal functional recovery requires regulation of the immunopathogenic process. The current treatments for MS are not completely effective because there is no effective therapy that can inhibit the functions of autoreactive T cells while inducing the remyelination and regeneration processes of neurons and thus prevent disability and irreversible axonal/neuronal damage [9,10]. In addition, there is no effective therapy for MS that can significantly modulate the functions of the cells of the CNS.

The pathogenic process of MS can be divided into inflammatory and degenerative phases. Therefore, to efficiently treat MS, it is necessary to develop a therapy that can specifically regulate the immune responses and that can also induce neuron regeneration. This will provide an effective regimen of immunomodulation and neuroprotection in MS patients. Several studies have shown many lines of evidence of neurodegeneration in MS, including the accumulation of amyloid precursor protein in neurons [11]; a reduction in the N-acetyl aspartate/creatine ratio, which reflects the degree of disability [12]; the finding of transected axons, which reflects the degree of inflammation within the active lesions [13]; damage to mitochondrial DNA and mitochondrial enzyme complexes [14]; and a reduction in axonal density in the white matter and spinal cords of MS patients [15,16].

Stem cell transplantation is a potential approach that can be used as a therapy to modulate the immunopathogenic process in MS to lead to neuron regeneration and treatment of the disease. Generally, stem cells can differentiate into various cell lineages with the ability to repair damaged tissue by reconstructing the tissue with new cells. The result is a recovery of lost functions, such as nerve conduction in patients with MS. Stem cells can perform their repair function by engrafting into the target tissue or by secreting paracrine factors that can trigger the repair pathways in the damaged tissue. Therefore, the utilization of stem cells in treating MS will rely on their ability to engraft into CNS tissues and then differentiate into neuron-like cells to replace the defective neurons or by secreting molecules that mediate the neuro-repair process in the CNS.

Generally, it is agreed that MSCs, which are derived from adult tissues, can attenuate the encephalitogenic manifestation of MS by suppressing the encephalitogenic T cells that mediate neuronal inflammation and damage [17–28]. The use of MSCs in EAE, the mouse model of MS, has shown that MSCs are able to modulate the immunopathogenesis of EAE and are also able to induce neuroprotection in EAE. Therefore, we will discuss the use of MSCs in EAE mice to investigate their effectiveness in attenuating the encephalitogenic process, possibly by inhibiting the functions of encephalitogenic T cell-mediated neuronal inflammation, neuronal demyelination and axon damage.

2. Experimental Autoimmune Encephalomyelitis (EAE)

The hypothesis that MS is an autoimmune disease was mainly based on the similarities observed between MS and its animal model, EAE. EAE is a demyelinating disease of the CNS that shares similar clinical and pathological features with MS. EAE is induced by immunizing animals with one of the myelin-derived antigens, such as proteolipid protein, myelin oligodendrocyte glycoprotein (MOG), or myelin basic protein (MBP) [29]. EAE is mediated by myelin-specific helper T cells, which are activated in the periphery and then translocate to the CNS, following permeabilization of the BBB [30,31]. Upon entering the CNS, T cells are reactivated by local and infiltrating active antigen presenting cells (APCs), such as dendritic cells, macrophages and microglia, resulting in inflammation and then subsequent neuronal demyelination and axonal damage [30,31].

Depending on the immunization protocol and the background of the mice, EAE can be induced in either an acute chronic progressive form or a relapsing-remitting form [32]. In addition, EAE can be induced by the adoptive transfer of activated myelin-specific helper T cells from EAE mice into naive recipient mice [33]. The EAE model is a useful tool with which to understand the immunopathogenesis of neuronal damage in EAE mice as well as to develop a therapy for MS [34,35].

2.1. Immune Cells in the Experimental Autoimmune Encephalomyelitis (EAE) Model

The inflammation present in MS and in its animal model, EAE, is largely mediated by autoreactive T cells that attack the CNS tissues. Dendritic cells that have been exposed to myelin-derived antigens secrete cytokines that induce the differentiation of naive T cells into effector T cells (Figure 1) in the lymph node. The differentiation of T helper 1 cells requires the presence of interferon-γ (IFN-γ) and IL-12, while IL-4 promotes the development of T helper 2 cells. In the mouse, the differentiation of Th17 cells is promoted by transforming growth factor-β (TGF-β), IL-6 and IL-21, whereas IL-1, IL-6 and IL-23 initiate Th17 differentiation in humans. The differentiation of regulatory T cells (Tregs) requires TGF-β [36].

However, it is still not clear how the inflammatory response is triggered in MS and EAE. It is possible that myelin antigens trigger the expansion of autoreactive lymphocytes in secondary lymphoid organs of susceptible MS patients and EAE mice. These immune cells then move from lymphoid organs into the circulation [37]. The expansion of inflammatory responses is also enhanced in MS patients and EAE mice due to poor Treg functioning [38]. Then, inflammatory cells adhere to and migrate across the BBB to infiltrate the tissues of the CNS, causing the characteristic inflammatory lesions surrounded by an area of neuronal demyelination and axonal loss [39]. There is evidence to suggest that the pathological heterogeneity in MS lesions is possibly a result of multiple distinct myelin-reactive effector T cells [40]. In addition, it has been noted that cytotoxic T-cells, which are present in MS lesions in significant numbers [41], may also contribute to tissue damage by attacking oligodendrocytes and by transecting axons [42,43].

2.1.1. T Helper 1 (Th1) and T Helper (Th17) Cells

The inflammatory role of Th1 cells in MS and EAE has been established. It has been reported that Th1 cells secrete inflammatory cytokines in the peripheral blood and in the CNS of affected subjects [44,45]. In addition, microglia activate Th1 cells in the CNS, which in turn activate macrophages to mediate myelin damage through the release of toxic mediators, such as tumor necrosis factor-alpha (TNF-α) [46]. Moreover, the adoptive transfer of myelin-specific CD4⁺ Th1 cells into naïve recipient mice can induce EAE in these mice [47–54]. Therefore, MS research was primarily based on IFN-γ-producing T cells because myelin-specific CD4⁺ Th1 cells were sufficient to induce EAE in mice. Several studies have demonstrated that altering IFN-γ production in the myelin-specific T cells prior to their transfer into recipient mice could decrease the encephalitogenic capacity of these CD4⁺ Th1 cells [52,55,56].

The essential role of IFN-γ in autoimmune encephalomyelitis was further assessed. It was shown that IFNγ-deficient mice were susceptible to EAE, and the disease appeared to be more severe in these mice as compared to control mice [57–59]. This result was further confirmed by using antibodies to neutralize IFN-γ [58,60]. In addition, the number of myelin-specific CD4⁺ T cells was shown to be increased in IFN-γ-deficient mice [61]. These results suggest that CD4⁺ Th1 cells can also induce EAE via a mechanism that is independent of IFN-γ. Thus, other cytokines may influence the pathogenic capacity of T cells.

Therefore, the focus of EAE research was shifted to investigations of the role of IL-12 in EAE because it is essential for the differentiation of Th1 cells. The p40 and p35 proteins, which together comprise IL-12, were deleted in mice, and EAE was then evaluated. It was shown that IL-12p40-deficient mice failed to develop EAE; however, EAE was induced in IL-12p35-deficient mice [62,63]. Because IL-12p40 is also a component of IL-23, the role of IL-23 was also evaluated in EAE mice. Because IL-23 also includes the p19 protein, the role of this protein in EAE pathogenesis was also evaluated in EAE mice. Interestingly, IL-12p40- and IL-12p19-deficient mice were resistant to EAE [64]. Accordingly, this result demonstrates that IL-23 and not IL-12 is crucial for the induction of EAE. In addition, IL-23 was found to promote the expansion of myelin-specific IL-17+ T cells, and these IL-17+ T cells were found to induce EAE [65]. Moreover, these Th17 cells produce IL-17, IL-21, IL-9, IL-22 and TNF-α and promote inflammation in EAE [53,65–67]. These findings led to the speculation that myelin-specific Th17 cells were the primary encephalitogenic T cell population in EAE and, possibly, in MS.

Several studies further confirmed the substantial role of Th17 cells in mediating neuronal immunopathogenesis in MS patients and in EAE mice. It has been reported that the number of Th17 cells increases in both the peripheral blood and the brain of MS patients [68,69]. In addition, it was shown that the brain endothelium of MS patients expresses high levels of the IL-17 receptor, and its ligand, IL-17, increases the permeability of the BBB to inflammatory cells [70]. Moreover, recent studies on EAE suggest that the initial inflammatory event in the CNS involves the migration of Th17 cells from the peripheral blood to the spinal fluid [71]. Subsequently, Th17 cells activate the BBB and allow the entry of Th1 cells into the CNS. The blockade of IL-17 was shown to reduce disease severity in EAE [72,73]. In addition, it was demonstrated that the disease severity of EAE was markedly reduced in IL-17-defective mice [74,75]. Moreover, it was reported that Th17 may induce EAE in mice via IL-9 because it was found that the neutralization of IL-9 can attenuate EAE [76]. Furthermore, the Th17 cells that induce EAE in mice were also found to be dependent on IL-1 because IL-1R-defective mice exhibited impaired Th17 cell activity and were also resistant to EAE induction [77].

Collectively, these studies demonstrated the significant roles of both Th1 and Th17 responses in mediating the immunopathogenesis of MS and its animal model, EAE. Therefore, Th1 and Th17 cells could be potential targets for the development of therapies for MS that modulate the immunopathogenic process to induce neuron regeneration.

2.1.2. T Helper 9 (Th9) Cells

TGF-β and IL-4 induce the development of T helper 9 cells, which produce IL-10 and IL-9 [78,79]. Although Th9 cells produce IL-10, they do not perform immunosuppressive functions. Th9 cells are different from Th1, Th17, and Foxp3-inducible Treg cells [78]. Recently, it was reported that IL-9 contributes to the induction of allergy and asthma [80]. In addition, it was shown that T helper 9 cells can also induce colitis and peripheral neuritis [6]. Moreover, MOG-specific Th9 cells were also shown to induce EAE and peripheral neuritis. Furthermore, IL-9, which is produced by the MOG-specific Th9 cells, can also activate mast cells, which induce demyelination [41].

2.1.3. γδ T Cells

γδ T cells provide the first line of defense against infection at mucosal sites. γδ T cells directly recognize ligands induced by stress, inflammation or infection. γδ T cells are also involved in both innate and adaptive immunity, and they play a role in both MS and EAE. The detection of γδ T cells in acute MS brain lesions has confirmed their potential role in the neuroimmunopathogenic process in MS [81]. This was further confirmed by the finding of these cells in the cerebrospinal fluid of MS patients [82]. Recently, IL-17 was shown to be produced by γδ T cells during infection [83,84]. In addition, these IL-17-producing γδ T cells were also reported to be present at high frequency in the brains of mice with EAE, and these cells increased the susceptibility of mice to EAE [85]. Thus, these studies confirmed the pathogenic role of γδ T cells in EAE. However, these cells exhibited both protective and pathogenic roles in the EAE model [86–93]. These conflicting results were attributed to the use of different mouse strains and the methods used to deplete γδ T cells.

2.1.4. Regulatory T Cells (Tregs)

Regulatory T cells (Tregs) include natural and inducible Treg cells. Natural Tregs (nTregs) are CD4⁺ CD25⁺ T cells, which develop in the thymus and then migrate to the periphery to perform their key role in immune homeostasis [94–96]. Adaptive Tregs, including Tr1, Th3 and various subsets of CD8⁺ Tregs (as discussed below), are derived in the periphery from naive T cells stimulated by antigen under the influence of the immunosuppressive cytokines IL-10 and TGF-β [97].

Various types of Treg cells were shown to play crucial roles in the regulation of autoimmune inflammation in MS patients and in EAE mice. It was reported that Tr1 responses and the frequency of nTreg cells are reduced in MS patients [98–101]. In mice, Tregs can control the development and severity of EAE. In addition, it was reported that transgenic mice expressing a T cell receptor specific for myelin antigen develop EAE, whereas non-transgenic CD4⁺ T cells prevented EAE, suggesting a suppressive role for CD4⁺ Treg cells [102,103]. Moreover, the transfer of CD4⁺CD25⁺ T cells into EAE mice can reduce the severity of the disease [104].

2.1.5. CD8<sup>+</sup> T Cells

Several studies demonstrated that CD8⁺ T cells have a crucial role in the pathogenesis of MS and EAE. CD8⁺ T cells were found in significant numbers in MS patients, as well as in EAE mice [41,105,106]. In addition, these cells contribute to tissue damage by attacking oligodendrocytes and by transecting axons [42,43]. However, a regulatory role for CD8⁺ T cells was also demonstrated in EAE mice. It was demonstrated that EAE is more severe in mice deficient in CD8⁺ T cells [106], and distinct subpopulations of CD8⁺ Treg cells, including CD8⁺ CD28⁻ and CD8⁺ CD122⁺ Treg cells, which can regulate EAE, were also identified [107,108].

Recently, CD8⁺CD28⁻ regulatory T cells have been characterized in humans. It has been shown for the first time that there is a population of CD8⁺CD28⁻ suppressor T cells that can suppress the alloreactivity of T helper cells [109–113]. The role of CD8⁺CD28⁻ regulatory T cells in a chronic model of EAE was also investigated, and it was shown that CD8⁺ T cells lacking CD28 expression are responsible for the regulatory functions of CD8⁺ T cells in EAE mice. These regulatory T cells can inhibit the activation of APCs and thus inhibit the activation of the encephalitogenic CD4⁺ Th1 cells [107].

The role of CD8⁺CD122⁺ regulatory T cells in EAE was also established. CD8⁺CD122⁺ regulatory T cells, which produce IL-10, can directly control CD8⁺ cells by suppressing CD8⁺ T cell production of IFN-γ, as well as by inhibiting the proliferation of CD8⁺ T cells [114,115]. It was demonstrated that the depletion of CD122⁺ cells can increase the duration of EAE symptoms in affected mice, while the transfer of CD8⁺CD122⁺ regulatory T cells into EAE mice can dramatically diminish the symptoms in EAE mice, thus demonstrating the protective role of CD8⁺CD122⁺ T cells in EAE [108]. In addition, in β2 microglobulin^−/− mice, where CD8⁺ T cells do not develop due to MHC I deficiency, a regulatory role for CD8⁺ T cells was demonstrated in EAE [116]. Moreover, CD8⁺ T cells isolated from EAE-recovered mice specifically inhibit MBP-activated CD4⁺ T-cells in vitro, and their depletion was also followed by recurrence of EAE. The suppressive function of these CD8⁺ T cells is restricted by the MHC I-like Qa-1 molecule (murine homologue of the human HLA-E), and the adoptive transfer of these cells prevented disease in MBP-immunized mice [117–119]. The failure of resistance to EAE in Qa-1-deficient mice is associated with the escape of Qa-1-deficient CD4⁺ cells from CD8⁺ T-cell suppression [120]. The suppressive role of CD8 T cells was further confirmed. It was shown that CD8⁺ Tregs, which express latency-associated peptide (LAP), can suppress myelin oligodendrocyte glycoprotein-specific immune responses in EAE via a mechanism that requires both IFN-γ and TGF-β [121]. These results provide evidence that CD8⁺ T cells are important in both inducing resistance to EAE and in abrogating recurrent relapsing episodes of pathogenic autoimmunity in vivo.

These studies demonstrated the essential roles that T cells may play in the immunopathogenesis of MS and its animal model, EAE. Therefore, T cells, including Th1, Th17, Th9, γδ T, CD4 regulatory T cells, CD8 T cells and CD8 regulatory T cells, are potential targets for the development of therapeutic strategies that aim to control T cell mediation of autoimmune processes in the EAE mouse model. Such therapeutic can be further developed into effective treatments for MS. However, recent studies revealed that MS is not only a T cell disease, as B cells were shown to significantly contribute to the disease. An increasing number of reports have demonstrated that B lymphocytes have an important role in the pathogenesis of MS. This includes the presence of B cells, plasma cells, autoantibodies and complement deposition in the blood, CSF and in CNS lesions in the majority of MS patients [122,123]. Most importantly, these autoantibodies contributed to the demyelination process [124–127], and they were reactive against myelin proteins and neurons [128,129]. In addition, a complement-mediated lysis of B cells effectively reduced MS disease activity, thus further confirming the pathogenic role of B cells in MS [130].

In addition, B cells function as APCs by presenting antigen to helper T cells. It was shown that B cells act as APCs in the periphery in MS patients [131]. Therefore, B cells may support the response of T helper cells in the periphery by activating naïve autoreactive cells and subsequently allowing them to enter the CNS. Thus, B cells may also have a regulatory function through direct contact with T cells. The costimulatory pathway, including CD154-CD40 and CD28-B7, is essential to inhibit the proliferation of T cells through the release of cytokines, such as IL-10 and TGF-β. It was reported that IL-10-producing B cells are deficient in MS patients [132]. Therefore, B cells can be one of the potential targets in MS research for the development of an effective therapy. Simply stated, we can inhibit the functions of naïve T cells via a mechanism that is dependent on the control of B cell functions.

Dendritic cells, which are a group of professional APCs, modulate adaptive immune responses [133]. Generally, inflammatory conditions induce the maturation of dendritic cells, which then induce T cell polarization [134]. Human immature dendritic cells can induce IL-10-producing Tregs and can also induce T-cell anergy [135]. Additionally, regulatory dendritic cells, which have a phenotype different from that of immature DCs, can promote peripheral tolerance and regulatory T cell development [135]. In MS, dendritic cells are among the cells that can infiltrate the CNS [136]. In addition, in SPMS, patients have high numbers of circulating mature dendritic cells compared with RRMS patients [137]. Therefore, dendritic cells are another potential therapeutic target for MS research with regard to the regulation of their functions, which will result in the modulation of the functions of autoreactive T cells, thereby improving or curing the disease.

Macrophages are also important in MS pathogenesis. Perivascular CNS macrophages can be activated by T helper 1 cytokines in MS lesions [138]. Macrophage activation can be either proinflammatory or anti-inflammatory, depending on the cytokine exposure. Macrophages exposed to IFN-γ are classified as proinflammatory M1 macrophages and are likely to contribute to myelin damage by phagocytosis and the release of neurotoxic mediators. Myelin- and neuroantigen-containing APCs were described in the cervical lymph nodes of healthy individuals, and these CNS antigen-containing APCs are increased in MS patients. These data suggest that myelin and neuronal antigens released from damaged CNS tissue may be captured by the CNS APCs and migrate into the cervical lymph nodes. Interestingly, neuronal antigens are presented by proinflammatory APCs, whereas myelin antigens are presented by anti-inflammatory APCs. Thus, pathogenic and regulatory CNS-specific T cells may be differentiated in the cervical lymph nodes [139]. These data provide another therapeutic pathway that can be pursued in the development of MS treatment. The modulation of macrophage functions would aid in regulating the autoimmune response of T cells, which would offer direct or indirect suppressive mechanisms by which to control the autoimmune responses and neuronal damage in MS patients.

Clearly, B cells, dendritic cells and macrophages can all contribute to the pathogenesis of MS; therefore, they are potential targets that should be pursued to develop effective therapies for MS. However, there is limited information regarding the modulating effects of MSCs on the functions of B cells, dendritic cells and macrophages in EAE. Therefore, our focus in this review will be on the effectiveness of MSCs in attenuating the encephalitogenic manifestation of EAE by suppressing the functions of the autoreactive T cells that mediate neuronal inflammation and damage.

3. Mesenchymal Stem Cells (MSCs)

Stem cells are specialized cells that are capable of self-renewal and multilineage differentiation. They fall into the two broad categories of embryonic stem cells (ESCs) and adult stem cells (ASCs). ESCs are pluripotent and differentiate into cell derivatives of the three germ layers: endoderm, ectoderm and mesoderm. ESCs are derived from the inner cell mass of the blastocyst; therefore, their use in cell-based therapy is controversial because of blastocyst destruction [140–143]. In contrast, the use of ASCs in cell-based therapy is less controversial because they are obtainable from a wide range of tissues, such as bone marrow, adipose tissue, placenta and umbilical cord. One important subset of ASCs is MSCs, which are multipotent cells that differentiate into mesenchymal cell lineages, including adipocytes, osteocytes, chondrocytes and myocytes [144,145]. However, MSCs can “transdifferentiate” and thereby cross lineage barriers, differentiating into different cell types, such as neurons (see below).

Mesenchymal stem cells have immunosuppressive properties that make them a therapeutic option that can be used to modulate the immunopathogenesis of multiple sclerosis and its animal model, EAE. Therefore, the effectiveness of MSCs in attenuating the encephalitogenic manifestation of EAE by suppressing the functions of the autoreactive T cells that mediate neuronal inflammation and damage has been examined.

Immunosuppressive Characteristics of Mesenchymal Stem Cells

Several studies have confirmed the immunosuppressive characteristics of MSCs. It was found that MSCs express MHC-I but lack the expression of MHC-II and costimulatory molecules [146–161]. In addition, MSCs suppress the immune responses of allogeneic lymphocytes [162,163]. In a mixed lymphocyte reaction, baboon or human bone marrow derived MSCs (BMMSCs) can inhibit the proliferation of allogeneic lymphocytes (Figure 2) [162,163]. In addition, human BMMSCs can also suppress the proliferative functions of T cells stimulated by antibodies to CD3 or CD28 [164]. Moreover, murine and human BMMSCs can inhibit the proliferation of lymphocytes stimulated with anti-CD3, IL2, IL7 or IL15 in vitro [165,166]. This inhibitory effect was shown to be partially mediated by IFN-γ [166]. Similarly, human placental MSCs and amniotic membrane MSCs can suppress the proliferation of allogeneic lymphocytes [146,148,149,167–170]. Furthermore, fetal liver MSCs can inhibit mitogen-stimulated lymphocytes [171,172], and it was similarly demonstrated that adipose-derived MSCs can inhibit T cell proliferation [18]. Moreover, it was shown that dental pulp MSCs (DP-MSCs) can suppress the proliferation of peripheral blood mononuclear cells [161]. Collectively, these studies showed that MSCs derived from different sources are immunosuppressive through the inhibition of the proliferation of allogeneic lymphocytes.

In addition, it was shown that MSCs can modulate the functions of both T and B lymphocytes. MSCs can inhibit the production of TNF-α and IFN-γ by CD4⁺ T and CD8⁺ T cells, whereas they can upregulate the expression of IL-10 and restore the secretion of IL-4 by CD4⁺ and CD8⁺ T cells [173] (Figure 2). In addition, fetal liver MSCs can down-regulate the production of IFN-γ and can increase the secretion of IL-10 in stimulated T cells [172]. Similarly, it was reported that MSCs derived from adipose tissues can enhance the secretion of IL-4, IL-5, and IL-10 by T cells [18]. In contact cultures, human MSCs were shown to suppress the ex vivo expansion of γδ T cells without modulating their cytotoxic function [174].

In addition, BMMSCs were found to selectively suppress the proliferative activities of both T and B lymphocytes via a mechanism that is mediated by programmed death 1 inhibitory molecule (PD-1) and its ligands PD ligand-1 (PD-L1) and PD ligand-2 (PD-L2) [175,176]. Moreover, BMMSCs can suppress the immune function of B cells stimulated by anti-CD40 or IL-4 [177]. This inhibitory effect of BMMSCs on B cells was also confirmed in other studies. It was shown that human BMMSCs can suppress the proliferation, differentiation and chemotactic activities of B cells [178,179]. Similarly, human placental MSCs can also suppress the immune responses of different populations of immune cells, including CD4⁺ and CD8⁺ T cells [148].

CD8⁺ cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells are effector cells with cytotoxic activities that can eliminate cancer or infected cells. CTLs are stimulated following their interaction with antigenic peptides expressed on MHC class I molecules. Human BMMSCs are recognized as targets by pre-stimulated alloreactive CTLs, and they can suppress the differentiation of CTL precursors into CTL effectors through the secretion of suppressive factors [180,181].

NK cells that are constitutively cytotoxic against allogeneic cells cannot lyse MSCs [148,181]. However, NK cells that are stimulated with IL-2 can lyse MSCs [182,183]. In addition, NK cells stimulated with IL-2 and IL-15 can lyse MSCs [184]. Therefore, these data on the ability of NK cells to lyse MSCs are contradictory. In addition, a recent study showed that CD8⁺ T and NK cells can lyse allogeneic MSCs [185]. Therefore, more research is necessary to study the susceptibility of MSCs to lysis by immune cells because this knowledge is indispensable for the development of an effective and safe MSC therapy. However, it is possible that MSCs have a transient effect on the inflammatory milieu in graft versus host disease (GVHD) because it was shown that MSCs can have long-lasting effects by passing on some of their effects to other cell types, such as regulatory T-cells [186,187]. Thus, this result indicates that the long-term effectiveness of MSCs would not be diminished if MSCs are lysed soon after infusion.

In addition, human BMMSCs can inhibit the proliferation of NK cells and the cytolytic activity of NK cells [188]. Moreover, Human BMMSCs can inhibit the production of IFN-γ by NK cells [188]. However, another study showed that human BMMSCs can significantly increase the secretion of IFN-γ by NK cells [183]. This inconsistency was attributed to the different effects that MSCs could have on NK cells. This possibility may depend on whether NK cells are triggered by IL-2 [183]. Another possibility is that the ratios of NK cells to MSCs used in different experimental settings may have differential activating or inhibitory effects on NK cells by MSCs. It is difficult to determine in vivo whether one or many NK cells interact simultaneously with an individual stem cell or vice versa.

Regarding the mechanism underlying the immunosuppressive function of MSCs, several reports suggest that cell-cell contact is not a compulsory requirement for the suppression of immune cell functions by MSCs [189–191]. Therefore, MSCs must produce soluble factors that mediate their immunosuppressive functions on immune cells. Several soluble factors were detected in the culture medium of MSCs, including stem cell factor (SCF), IL-6, IL-8, IL-10, IL-12, IFN-γ, PGE₂ (prostaglandin E₂), vascular endothelial growth factor (VEGF), macrophage colony-stimulating factor (M-CSF), hepatocyte growth factor (HGF) and transforming growth factor -β1 (TGF-β1) [146,161,188,192,193].

The immunosuppressive capacity of MSCs in vivo was also confirmed in various studies [191]. It was reported that the intravenous injection of MSCs can prolong the survival of an allogeneic skin graft in baboons [162]. Likewise, the injection of murine BMMSCs into mice can stimulate the survival of allogeneic skin grafts in mice [194]. In addition, it was shown that MSCs were not rejected following their transplantation into allogeneic immunocompetent mice [190]. However, the subcutaneous injection of melanoma cells resulted in tumor growth in allogeneic recipients only when MSCs were co-injected [190]. Although the possible side effects of immunosuppression induced by MSCs need to be investigated in more detail, the effectiveness of MSCs for many therapeutic applications remains of great interest. Recently, it was revealed that the injection of mouse MSCs prolonged the survival of skin transplants in mice [195]. In addition, the immunosuppressive effect of human MSCs on the severity of bleomycin-induced inflammation and fibrosis in an animal model was evaluated. The presence of transplanted MSCs reduced the neutrophil infiltration and significantly decreased the inflammation, as well as the severity of lung fibrosis, in mice treated with allogeneic or xenogeneic placenta-derived cells [196].

The therapeutic efficacy of MSCs in the murine model of MS, EAE, was also reported (see below). In addition, the intravenous injection of baboons with autologous or allogeneic baboon MSCs together with hematopoietic progenitor cells facilitated a faster hematopoietic recovery [197]. This result was further confirmed by a recent study showing that allogeneic BMMSCs can reduce the severity of GVHD in an F1 model of acute GVHD [198].

Therefore, the immunosuppressive features of MSCs, together with their ability to differentiate into neuronal lineages, support the use of MSCs in EAE to modulate the immunopathogenic process underlying the neuronal damage, as well as to offer neuroprotection in EAE, to develop therapeutic strategies for MS.

4. The Use of MSCs in Clinical Experimental Autoimmune Encephalomyelitis (EAE) 4.1. Immune Modulatory Effect of MSCs in EAE

Several studies showed that MSCs exert immunoinhibitory functions on immune cells in vitro and in vivo [191]. These characteristics, together with the ability of MSCs to differentiate into neuron-like cells [199] and migrate to the CNS [200], promoted the use of MSCs in EAE treatment. Several studies confirmed the differentiation of MSCs into neurons. Rat and human BMMSCs were shown to differentiate into neurons in vitro [201,202]. The differentiated cells expressed a variety of neuron-specific markers, including neuron-specific enolase, tau, neurofilament M, neuron-specific nuclear protein, β-III-tubulin, and synaptophysin [202,203]. Pioneering studies also demonstrated the differentiation of BMMSCs into neural cell types in vivo. The transplantation of MSCs into mouse ventricles or striatum resulted in their expression of astrocytic traits [199,204]. It was shown for the first time that after the injection of mouse BMMSCs into the lateral ventricle of neonatal mice, MSCs migrated throughout the forebrain and cerebellum and differentiated into astrocytes in the striatum, the hippocampus and the reticular formation of the brain stem [199]. In addition, MSCs were found within neuron-rich regions and within the cerebellum [199]. The differentiation of MSCs into neurons was further confirmed in a study of the differentiation of mouse BMMSCs into phenotypic neural cells in ischemic animals [205]. Similarly, human BMMSCs implanted into ischemic rats, increased neurogenesis in these rats [206]. In addition, it was shown that human BMMSCs can differentiate into neural cells following their implantation in the brain of ischemic rats [207]. Moreover, the differentiation of MSCs into neurons was also demonstrated in the embryonic rat brain [208], and the stereotactic implantation of mouse MSCs into the brain of rats demonstrated the differentiation of implanted MSCs into mature neurons [209]. Recently, the transplantation of human placental MSCs into the striatum in a rat model of Parkinson’s disease also confirmed the ability of MSCs to differentiate into neurons [210]. Collectively, these studies support the ability of MSCs to differentiate into neurons.

The ability of BMMSCs to modulate the immunopathogenic process, leading to neuroprotection in EAE, was also demonstrated in several studies. It was shown that BMMSCs can improve neuronal recovery in EAE, possibly by stimulating oligodendrogenesis and reducing the inflammatory infiltrates, demyelination and axonal loss in the CNS of EAE mice by inhibiting autoreactive T cell responses [20,28,211,212]. In addition, the accumulation of BMMSCs in the tissues of the CNS and lymphoid organs of EAE mice reduced the severity of the disease by modulating the functions of T cells, as demonstrated by the following: (1) decreased inflammatory cytokine (INF-γ and IL-17) secretion by Th1 and Th17 cells; (2) increased numbers of Th2 cells and regulatory T cells and their secretion of anti-inflammatory cytokines; (3) decreased numbers of Th1 and Th17 T cells; and (4) increased numbers of oligodendrocytes in the CNS tissues of EAE mice (Figure 3) [17,21,26,27,213].

The neuroprotective effect of MSCs in EAE mice was further confirmed. It was shown that the administration of MSCs to EAE mice suppressed the clinicopathological manifestations of EAE and prevented axonal damage [23]. In this study, intraventricularly injected BMMSCs were detected in the inflamed CNS tissues of the EAE mice, and these MSCs exhibited features of neuronal lineages [23]. In addition, the intravenously injected MSCs migrated to the lymph nodes, which were associated with immunomodulatory effects, as demonstrated by the decrease in the immune cell infiltrate in the CNS [23]. Other studies confirmed the neuroprotective property of MSCs. The treatment of EAE mice with human endometrial MSCs significantly reduced EAE manifestations as a result of a reduction in Th1 and Th17 cell infiltrates in the CNS tissues of EAE mice [214]. This reduction in the target organ was probably a result of MSC-induced regulatory mechanisms in the periphery, as demonstrated by the up-regulation of IL-10, IL-27, immune suppressive enzyme, indoleamine-2,3-dioxygenase (IDO), and Foxp3 expression, thus indicating a higher percentage of putative Tregs [214]. In addition, BMMSCs that were transplanted intracerebroventricularly into EAE mice delayed the onset of symptoms and increased animal survival via mechanisms that possibly involved both immunomodulation and neuroprotection [215].

Recently, it was shown that with the intravenous administration of adipose-derived MSCs to EAE mice before disease onset, MSCs homed into lymphoid organs and migrated inside the CNS. These MSCs reduced the severity of EAE by immune modulation and decreased spinal cord inflammation and demyelination [18]. In addition, the administration of these adipose-derived MSCs to animals with chronic EAE ameliorated the disease course and reduced both demyelination and axonal loss while inducing Th2-type cytokine production [18]. Moreover, the infiltration of these MSCs within demyelinated areas was accompanied by increased numbers of endogenous oligodendrocyte progenitors [18]. The potential neuroprotective role of MSCs in EAE mice was also further confirmed. It was shown that human BMMSCs can migrate into the spinal cord in mice with EAE and that this significantly reduced the clinical disease severity [216]. The injected MSCs accumulated in the demyelinated areas, and these cells expressed neural markers [216]. In addition, the number of spinal cord white matter lesions and areas of white matter demyelination were reduced and were associated with decreased inflammatory infiltration after treatment with MSCs [216]. A recent study further confirmed the modulatory effects of MSCs on the immunopathogenic process in EAE. The transplantation of human placental MSCs into EAE mice yielded a decrease in disease severity in the transplanted animals via a mechanism that depends on the anti-inflammatory protein TNF-α-stimulated gene/protein 6 (TSG-6) [217].

These results demonstrate that MSCs have the therapeutic potential of suppressing the autoimmune response in early phases of disease and of inducing local neuroregeneration by endogenous progenitors in animals with established disease. In addition, MSCs were also shown to ameliorate the disease severity in EAE mice by the secretion of PGE2, which is dependent upon IDO for its immunosuppressive function [25]. The role of soluble factors in modulating the pathogenesis of EAE was confirmed in a recent study demonstrating that conditioned medium from human MSCs can reduce the functional deficits in EAE mice and can also promote the development of oligodendrocytes and neurons [218]. In agreement with this finding, it was found that human BMMSCs produce soluble factors that are important for mediating axon outgrowth and recovery in rats with injured spinal cords [219]. In addition, it was shown that BMMSCs can induce oligodendrocyte differentiation via factors produced by MSCs [220]. Moreover, when neural progenitor cells (NPCs), which were pre-differentiated in vitro by MSC-derived soluble factors, were transplanted in situ together with MSCs into hippocampal slice cultures, the grafted NPCs survived, and the majority of them differentiated into oligodendrocytes and neural progenitors [221]. Therefore, there is a general agreement regarding the effects of MSCs on improving the clinical manifestations of EAE in mice. However, the immunomodulatory properties of MSCs are not the only mechanisms that could explain their therapeutic plasticity. MSCs express a broad spectrum of regulatory proteins that may mediate their therapeutic functions. In addition, the ability of MSCs to respond to injuries depends on their microenvironment, regardless of whether they have a low engraftment rate in vivo [222]. MSCs produce cytokines and a variety of soluble factors that regulate several biological activities [191]. This suggests that MSCs can promote the survival of other cells and thus play a major role in the maintenance of tissue homeostasis [223].

4.2. Neuroprotective Properties of MSCs

The ability of MSCs to home to injured tissues and to transdifferentiate into multiple cell types in vivo was disputed by recent observations demonstrating that only small numbers of the injected MSCs can engraft into tissues and that the supernatant of MSC culture is sufficient to block hepatic failure [224,225]. In addition, several in vitro studies demonstrated that MSCs exert significant biological effects on target cells without the need for cell contact. Therefore, these and other in vitro and in vivo studies generated the hypothesis that the therapeutic effects of MSCs depend significantly on soluble factors secreted by MSCs and that these factors may mediate the MSC induction of tissue repair.

A number of in vitro studies showed that MSCs have the potential to rescue neurons from apoptosis [226–228]. Thus, this anti-apoptotic function of MSCs, together with their immunomodulatory properties, explain the reduction in axonal loss observed in EAE mice treated with MSCs [20,23,212]. In addition, MSCs secrete neurotrophic molecules, which would further explain how MSCs can induce remyelination in EAE mice [18,211,229].

The neuroprotective property of MSCs in EAE as discussed above was supported by several studies utilizing experimental models of stroke and spinal cord injury. For example, after the direct injection of BMMSCs into demyelinated spinal cords, they promoted remyelination [230]. In another study involving the transplantation of MSCs into the subarachnoid space of the lumbar spine, the MSCs infiltrated into the spinal cord parenchyma and then differentiated into immature neurons or glial cells. This was followed by complete transection and motor improvement [231]. In addition, BMMSCs were shown to improve the survival of motor neurons following their transplantation into the lumbar spinal cord in an animal model of human amyotrophic lateral sclerosis [232].

In a model of stroke, the intravenous administration of MSCs increased the expression of basic fibroblast growth factor, reduced apoptosis, promoted endogenous neurogenesis, and improved functional recovery [233]. MSCs can directly promote the plasticity of damaged neurons or stimulate glial cells to secrete neurotrophins (e.g., brain-derived neurotrophic factor (bDNF) and nerve growth factor (NGF)), reduce apoptosis in the penumbral zone of the lesion and support the proliferation of the endogenous cells in the subventricular zone [234]. In addition, the implantation of BMMSCs in the hippocampus of immunodeficient mice stimulated the proliferation, migration and differentiation of the endogenous neural stem cells, which survived as differentiated neural cells via their secretion of various trophic factors, including NGF, vascular endothelial growth factor (VEGF), ciliary neurotrophic factor (CNTF), basic fibroblast growth factor (FGF-2) and BMI-1 [235].

This indirect effect of MSCs on the improvement of neurogenesis was further supported in a mouse model of global ischemia, where MSCs improved neurological function and prevented neuronal cell death in the hippocampus via a mechanism that was mediated by the local microglia, which expressed high levels of neuroprotective factors, such as insulin-like growth factor 1 (IGF-1) [236]. This neuroprotective effect of MSCs on microglia was further confirmed. It was shown that MSCs can inhibit the production of inflammatory factors, including nitric oxide (NO), tumor necrosis factor, IL1-β and reactive oxygen species (ROS), by activated microglia, thus preventing neuronal damage via the production of neurotrophic factors, which are likely to be involved in neuroprotection [237]. In agreement with these results, it was reported that the cell death of dopaminergic neurons induced by activated microglia can be inhibited by MSCs [220,238]. In addition to the neuroprotective effects of MSCs on activated microglia, MSCs can significantly inhibit the up-regulation of molecules involved in oxyradical detoxification occurring in EAE [239]. Similarly, MSCs can resolve the increase of oxidative stress-associated proteins in neurons exposed to H₂O₂ [239]. This result suggests that MSCs can inhibit the neuroinflammatory process that is mediated by proinflammatory and oxidative stress molecules secreted by macrophages and microglia. However, microglia are not the only neural cell type targeted by MSCs; it was shown that MSCs can also inhibit the differentiation of neural precursor cells (NPCs) into astrocytes in vitro [220,229].

MSC transplantation represents an attractive therapeutic approach for MS treatment. However, many questions are essential to be answered before the use of MSCs in MS patients to determine their therapeutic potential. For example, it is essential to know the effect of ageing on MSC biology, since several studies indicate that ageing can affect the proliferation and differentiation capacities of MSCs. It has been shown that MSCs undergo replicative senescence, loss of differentiation capacity and ultimate growth arrest with increasing time in culture [240–250]. However, another study showed that aged MSCs have a higher proliferation rate than young MSCs [251] while another study did not find differences in the proliferation potential between aged and young MSCs [247]. These controversial results were attributed to species, gender and donor age of animals used in these studies and also to differences in the conditions of cell culture. However, these studies suggest that aging may change but not block the proliferation of MSCs. Regarding the differentiation potential of MSCs, the majority of studies reported an age-related reduction in the osteogenic potential [244,246,249–251]. In addition, this decrease in osteogenic capacity was associated with increased ability of aged MSCs to differentiate into adipocytes [244]. Since, these studies demonstrated that aging has an effect on the biological behaviours of MSCs following their long expansion time in culture; therefore this would not prevent their use in cell based therapies. More studies are necessary in order to determine the effects of aging on the immune- suppressive and neuroprotection functions of MSCs in vitro and in vivo before the use of MSCs in MS patients. It would be essential to compare the capacity of young versus aged MSCs in providing neuroprotection and neuroregeneration effects in EAE mice.

5. Conclusions

Evidence is increasing in support of the use of MSCs in treating neurological diseases, such as MS, via modulating the immunopathogenic process and promoting the repair of damaged neurons. In addition, the current data available in the literature suggest that the neurotherapeutic effect of MSCs is possibly mediated via a direct contact between MSCs and damaged neuronal cells or via soluble factors that are secreted by MSCs. MSCs secrete anti-inflammatory, anti-apoptotic and neurotrophic factors. These soluble factors can induce protective phenotypic features in other cells, such as microglia, and can also induce the remyelination process, thus maintaining the neuroprotective effects observed in experimental animal models of MS and other neurological disorder models. Therefore, these immunomodulatory and protective properties of MSCs may provide the basis to translate the neurotherapeutic effects of MSCs seen in animal models into humans in well-designed and carefully controlled clinical studies.

Acknowledgements

We wish to acknowledge the financial support from KAIMRC Grant No. RC08/114 and KACST Grant No. ARP-29-186.

Conflict of Interest

The authors have no conflicts of interest to declare.

References 1

Noseworthy

J.H.

Lucchinetti

Rodriguez

Weinshenker

B.G.

Multiple sclerosis

N. Engl. J. Med2000343938952

10.1056/NEJM200009283431307

11006371

Frohman

E.M.

Racke

M.K.

Raine

C.S.

Multiple sclerosis—The plaque and its pathogenesis

N. Engl. J. Med2006354942955

10.1056/NEJMra052130

16510748

Martin

Immunological aspects of experimental allergic encephalomyelitis and multiple sclerosis and their application for new therapeutic strategies

J. Neural Transm. Suppl1997495367

9266414

Compston

Coles

Multiple sclerosis

Lancet200837215021517

10.1016/S0140-6736(08)61620-7

18970977

Ebers

G.C.

Environmental factors and multiple sclerosis

Lancet Neurol20087268277

10.1016/S1474-4422(08)70042-5

18275928

Duquette

Pleines

Girard

Charest

Senecal-Quevillon

Masse

The increased susceptibility of women to multiple sclerosis

Can. J. Neurol. Sci199219466471

1423044

McDonald

W.I.

Sears

T.A.

The effects of experimental demyelination on conduction in the central nervous system

Brain197093583598

10.1093/brain/93.3.583

4319185

Kuehn

B.M.

Scientists probe strategies to repair neuron damage in multiple sclerosis

J. Am. Med. Assoc2011305871872874

10.1001/jama.2011.212

Karussis

Grigoriadis

Polyzoidou

Grigoriadis

Slavin

Abramsky

Neuroprotection in multiple sclerosis

Clin. Neurol. Neurosurg2006108250254

10.1016/j.clineuro.2005.11.007

16413962

Steinman

Multiple sclerosis: A two-stage disease

Nat. Immunol20012762764

10.1038/ni0901-762

11526378

Gehrmann

Banati

R.B.

Cuzner

M.L.

Kreutzberg

G.W.

Newcombe

Amyloid precursor protein (APP) expression in multiple sclerosis lesions

Glia199515141151

10.1002/glia.440150206

8567065

Foong

Rozewicz

Davie

C.A.

Thompson

A.J.

Miller

D.H.

Ron

M.A.

Correlates of executive function in multiple sclerosis: The use of magnetic resonance spectroscopy as an index of focal pathology

J. Neuropsychiatry Clin. Neurosci1999114550

9990555

Trapp

B.D.

Peterson

Ransohoff

R.M.

Rudick

Mork

Axonal transection in the lesions of multiple sclerosis

N. Engl. J. Med1998338278285

10.1056/NEJM199801293380502

9445407

Vladimirova

O’Connor

Cahill

Alder

Butunoi

Kalman

Oxidative damage to DNA in plaques of MS brains

Mult. Scler19984413418

9839301

Lovas

Szilagyi

Majtenyi

Palkovits

Komoly

Axonal changes in chronic demyelinated cervical spinal cord plaques

Brain2000123308317

10.1093/brain/123.2.308

10648438

Evangelou

Esiri

M.M.

Smith

Palace

Matthews

P.M.

Quantitative pathological evidence for axonal loss in normal appearing white matter in multiple sclerosis

Ann. Neurol200047391395

10.1002/1531-8249(200003)47:3<391::AID-ANA20>3.0.CO;2-J

10716264

Bai

Lennon

D.P.

Eaton

Maier

Caplan

A.I.

Miller

S.D.

Miller

R.H.

Human bone marrow-derived mesenchymal stem cells induce Th2-polarized immune response and promote endogenous repair in animal models of multiple sclerosis

Glia20095711921203

10.1002/glia.20841

19191336

Constantin

Marconi

Rossi

Angiari

Calderan

Anghileri

Gini

Bach

S.D.

Martinello

Bifari

Adipose-derived mesenchymal stem cells ameliorate chronic experimental autoimmune encephalomyelitis

Stem. Cells20092726242635

10.1002/stem.194

19676124

Einstein

Grigoriadis

Mizrachi-Kol

Reinhartz

Polyzoidou

Lavon

Milonas

Karussis

Abramsky

Ben-Hur

Transplanted neural precursor cells reduce brain inflammation to attenuate chronic experimental autoimmune encephalomyelitis

Exp. Neurol2006198275284

10.1016/j.expneurol.2005.11.007

16472805

Gerdoni

Gallo

Casazza

Musio

Bonanni

Pedemonte

Mantegazza

Frassoni

Mancardi

Pedotti

Mesenchymal stem cells effectively modulate pathogenic immune response in experimental autoimmune encephalomyelitis

Ann. Neurol200761219227

10.1002/ana.21076

17387730

Grigoriadis

Lourbopoulos

Lagoudaki

Frischer

J.M.

Polyzoidou

Touloumi

Simeonidou

Deretzi

Kountouras

Spandou

Variable behavior and complications of autologous bone marrow mesenchymal stem cells transplanted in experimental autoimmune encephalomyelitis

Exp. Neurol20112307889

10.1016/j.expneurol.2011.02.021

21440544

Karussis

Kassis

Kurkalli

B.G.

Slavin

Immunomodulation and neuroprotection with mesenchymal bone marrow stem cells (MSCs): A proposed treatment for multiple sclerosis and other neuroimmunological/neurodegenerative diseases

J. Neurol. Sci2008265131135

10.1016/j.jns.2007.05.005

17610906

Kassis

Grigoriadis

Gowda-Kurkalli

Mizrachi-Kol

Ben-Hur

Slavin

Abramsky

Karussis

Neuroprotection and immunomodulation with mesenchymal stem cells in chronic experimental autoimmune encephalomyelitis

Arch. Neurol200865753761

10.1001/archneur.65.6.753

18541795

Zhu

Wang

Zheng

Liu

Overexpression of CNTF in Mesenchymal Stem Cells reduces demyelination and induces clinical recovery in experimental autoimmune encephalomyelitis mice

J. Neuroimmunol20092065869

10.1016/j.jneuroim.2008.10.014

19081144

Matysiak

Orlowski

Fortak-Michalska

Jurewicz

Selmaj

Immunoregulatory function of bone marrow mesenchymal stem cells in EAE depends on their differentiation state and secretion of PGE2

J. Neuroimmunol2011233106111

10.1016/j.jneuroim.2010.12.004

21354631

Rafei

Birman

Forner

Galipeau

Allogeneic mesenchymal stem cells for treatment of experimental autoimmune encephalomyelitis

Mol. Ther20091717991803

10.1038/mt.2009.157

19602999

Rafei

Campeau

P.M.

Aguilar-Mahecha

Buchanan

Williams

Birman

Yuan

Young

Y.K.

Boivin

M.N.

Forner

Mesenchymal stromal cells ameliorate experimental autoimmune encephalomyelitis by inhibiting CD4 Th17 T cells in a CC chemokine ligand 2-dependent manner

J. Immunol200918259946002

10.4049/jimmunol.0803962

19414750

Zappia

Casazza

Pedemonte

Benvenuto

Bonanni

Gerdoni

Giunti

Ceravolo

Cazzanti

Frassoni

Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy

Blood200510617551761

10.1182/blood-2005-04-1496

15905186

Stromnes

I.M.

Goverman

J.M.

Active induction of experimental allergic encephalomyelitis

Nat. Protoc2006118101819

10.1038/nprot.2006.285

17487163

Furtado

G.C.

Marcondes

M.C.

Latkowski

J.A.

Tsai

Wensky

Lafaille

J.J.

Swift entry of myelin-specific T lymphocytes into the central nervous system in spontaneous autoimmune encephalomyelitis

J. Immunol200818146484655

18802067

O’Connor

R.A.

Prendergast

C.T.

Sabatos

C.A.

Lau

C.W.

Leech

M.D.

Wraith

D.C.

Anderton

S.M.

Cutting edge: Th1 cells facilitate the entry of Th17 cells to the central nervous system during experimental autoimmune encephalomyelitis

J. Immunol200818137503754

18768826

Steinman

Assessment of animal models for MS and demyelinating disease in the design of rational therapy

Neuron199924511514

10.1016/S0896-6273(00)81107-1

10595504

Stromnes

I.M.

Goverman

J.M.

Passive induction of experimental allergic encephalomyelitis

Nat. Protoc2006119521960

10.1038/nprot.2006.284

17487182

Teitelbaum

Meshorer

Hirshfeld

Arnon

Sela

Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide

Eur. J. Immunol19711242248

10.1002/eji.1830010406

5157960

Yednock

T.A.

Cannon

Fritz

L.C.

Sanchez-Madrid

Steinman

Karin

Prevention of experimental autoimmune encephalomyelitis by antibodies against α4β1 integrin

Nature19923566366

10.1038/356063a0

1538783

Sakaguchi

Powrie

Emerging challenges in regulatory T cell function and biology

Science2007317627629

10.1126/science.1142331

17673654

Lopez-Diego

R.S.

Weiner

H.L.

Novel therapeutic strategies for multiple sclerosis—A multifaceted adversary

Nat. Rev. Drug Discov20087909925

10.1038/nrd2358

18974749

Viglietta

Baecher-Allan

Weiner

H.L.

Hafler

D.A.

Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis

J. Exp. Med2004199971979

10.1084/jem.20031579

15067033

Leussink

V.I.

Zettl

U.K.

Jander

Pepinsky

R.B.

Lobb

R.R.

Stoll

Toyka

K.V.

Gold

Blockade of signaling via the very late antigen (VLA-4) and its counterligand vascular cell adhesion molecule-1 (VCAM-1) causes increased T cell apoptosis in experimental autoimmune neuritis

Acta Neuropathol2002103131136

10.1007/s004010100444

11810178

Jager

Dardalhon

Sobel

R.A.

Bettelli

Kuchroo

V.K.

Th1, Th17, and Th9 effector cells induce experimental autoimmune encephalomyelitis with different pathological phenotypes

J. Immunol200918371697177

10.4049/jimmunol.0901906

19890056

Skulina

Schmidt

Dornmair

Babbe

Roers

Rajewsky

Wekerle

Hohlfeld

Goebels

Multiple sclerosis: Brain-infiltrating CD8+ T cells persist as clonal expansions in the cerebrospinal fluid and blood

Proc. Natl. Acad. Sci. USA200410124282433

10.1073/pnas.0308689100

14983026

Medana

Martinic

M.A.

Wekerle

Neumann

Transection of major histocompatibility complex class I-induced neurites by cytotoxic T lymphocytes

Am. J. Pathol2001159809815

10.1016/S0002-9440(10)61755-5

11549572

Giuliani

Goodyer

C.G.

Antel

J.P.

Yong

V.W.

Vulnerability of human neurons to T cell-mediated cytotoxicity

J. Immunol2003171368379

12817020

Chitnis

The role of CD4 T cells in the pathogenesis of multiple sclerosis

Int. Rev. Neurobiol2007794372

17531837

Hedegaard

C.J.

Krakauer

Bendtzen

Lund

Sellebjerg

Nielsen

C.H.

T helper cell type 1 (Th1), Th2 and Th17 responses to myelin basic protein and disease activity in multiple sclerosis

Immunology2008125161169

10.1111/j.1365-2567.2008.02837.x

18397264

Delgado

Sheremata

W.A.

The role of CD4+ T-cells in the development of MS

Neurol. Res200628245249

10.1179/016164106X98107

16687048

Pettinelli

C.B.

McFarlin

D.E.

Adoptive transfer of experimental allergic encephalomyelitis in SJL/J mice after in vitro activation of lymph node cells by myelin basic protein: Requirement for Lyt 1+ 2- T lymphocytes

J. Immunol198112714201423

6168690

McDonald

A.H.

Swanborg

R.H.

Antigen-specific inhibition of immune interferon production by suppressor cells of autoimmune encephalomyelitis

J. Immunol198814011321138

2963860

Ando

D.G.

Clayton

Kono

Urban

J.L.

Sercarz

E.E.

Encephalitogenic T cells in the B10.PL model of experimental allergic encephalomyelitis (EAE) are of the Th-1 lymphokine subtype

Cell Immunol1989124132143

10.1016/0008-8749(89)90117-2

2478300

Waldburger

K.E.

Hastings

R.C.

Schaub

R.G.

Goldman

S.J.

Leonard

J.P.

Adoptive transfer of experimental allergic encephalomyelitis after in vitro treatment with recombinant murine interleukin-12. Preferential expansion of interferon-gamma-producing cells and increased expression of macrophage-associated inducible nitric oxide synthase as immunomodulatory mechanisms

Am. J. Pathol1996148375382

8579100

Yura

Takahashi

Serada

Koshio

Nakagami

Yuki

Kiyono

Role of MOG-stimulated Th1 type “light up” (GFP+) CD4+ T cells for the development of experimental autoimmune encephalomyelitis (EAE)

J. Autoimmun2001171725

10.1006/jaut.2001.0520

11488634

Lovett-Racke

A.E.

Rocchini

A.E.

Choy

Northrop

S.C.

Hussain

R.Z.

Ratts

R.B.

Sikder

Racke

M.K.

Silencing T-bet defines a critical role in the differentiation of autoreactive T lymphocytes

Immunity200421719731

10.1016/j.immuni.2004.09.010

15539157

Gocke

A.R.

Cravens

P.D.

Ben

L.H.

Hussain

R.Z.

Northrop

S.C.

Racke

M.K.

Lovett-Racke

A.E.

T-bet regulates the fate of Th1 and Th17 lymphocytes in autoimmunity

J. Immunol200717813411348

17237380

Hemmer

Cepok

Zhou

Sommer

Multiple sclerosis—A coordinated immune attack across the blood brain barrier

Curr. Neurovasc. Res20041141150

10.2174/1567202043480152

16185190

Racke

M.K.

Bonomo

Scott

D.E.

Cannella

Levine

Raine

C.S.

Shevach

E.M.

Rocken

Cytokine-induced immune deviation as a therapy for inflammatory autoimmune disease

J. Exp. Med199418019611966

10.1084/jem.180.5.1961

7525845

Racke

M.K.

Burnett

Pak

S.H.

Albert

P.S.

Cannella

Raine

C.S.

McFarlin

D.E.

Scott

D.E.

Retinoid treatment of experimental allergic encephalomyelitis. IL-4 production correlates with improved disease course

J. Immunol1995154450458

7527821

Willenborg

D.O.

Fordham

Bernard

C.C.

Cowden

W.B.

Ramshaw

I.A.

IFN-gamma plays a critical down-regulatory role in the induction and effector phase of myelin oligodendrocyte glycoprotein-induced autoimmune encephalomyelitis

J. Immunol199615732233227

8871615

Lublin

F.D.

Knobler

R.L.

Kalman

Goldhaber

Marini

Perrault

D’Imperio

Joseph

Alkan

S.S.

Korngold

Monoclonal anti-gamma interferon antibodies enhance experimental allergic encephalomyelitis

Autoimmunity199316267274

10.3109/08916939309014645

7517706

Ferber

I.A.

Brocke

Taylor-Edwards

Ridgway

Dinisco

Steinman

Dalton

Fathman

C.G.

Mice with a disrupted IFN-gamma gene are susceptible to the induction of experimental autoimmune encephalomyelitis (EAE)

J. Immunol199615657

8598493

Heremans

Dillen

Groenen

Martens

Billiau

Chronic relapsing experimental autoimmune encephalomyelitis (CREAE) in mice: Enhancement by monoclonal antibodies against interferon-γ

Eur. J. Immunol19962623932398

10.1002/eji.1830261019

8898951

Chu

C.Q.

Wittmer

Dalton

D.K.

Failure to suppress the expansion of the activated CD4 T cell population in interferon γ-deficient mice leads to exacerbation of experimental autoimmune encephalomyelitis

J. Exp. Med2000192123128

10.1084/jem.192.1.123

10880533

Becher

Durell

B.G.

Noelle

R.J.

Experimental autoimmune encephalitis and inflammation in the absence of interleukin-12

J. Clin. Invest2002110493497

12189243

Gran

Zhang

G.X.

Chen

X.H.

Ventura

E.S.

Kamoun

Rostami

IL-12p35-deficient mice are susceptible to experimental autoimmune encephalomyelitis: Evidence for redundancy in the IL-12 system in the induction of central nervous system autoimmune demyelination

J. Immunol200216971047110

12471147

Cua

D.J.

Sherlock

Chen

Murphy

C.A.

Joyce

Seymour

Lucian

Kwan

Churakova

Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain

Nature2003421744748

10.1038/nature01355

12610626

Langrish

C.L.

Chen

Blumenschein

W.M.

Mattson

Basham

Sedgwick

J.D.

McClanahan

Kastelein

R.A.

Cua

D.J.

IL-23 drives a pathogenic T cell population that induces autoimmune inflammation

J. Exp. Med2005201233240

10.1084/jem.20041257

15657292

Mangan

P.R.

Harrington

L.E.

O’Quinn

D.B.

Helms

W.S.

Bullard

D.C.

Elson

C.O.

Hatton

R.D.

Wahl

S.M.

Schoeb

T.R.

Weaver

C.T.

Transforming growth factor-β induces development of the T(H)17 lineage

Nature2006441231234

10.1038/nature04754

16648837

Harrington

L.E.

Hatton

R.D.

Mangan

P.R.

Turner

Murphy

T.L.

Murphy

K.M.

Weaver

C.T.

Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages

Nat. Immunol2005611231132

10.1038/ni1254

16200070

Durelli

Conti

Clerico

Boselli

Contessa

Ripellino

Ferrero

Eid

Novelli

T-helper 17 cells expand in multiple sclerosis and are inhibited by interferon-β

Ann. Neurol200965499509

10.1002/ana.21652

19475668

Tzartos

J.S.

Friese

M.A.

Craner

M.J.

Palace

Newcombe

Esiri

M.M.

Fugger

Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis

Am. J. Pathol2008172146155

10.2353/ajpath.2008.070690

18156204

Kebir

Kreymborg

Ifergan

Dodelet-Devillers

Cayrol

Bernard

Giuliani

Arbour

Becher

Prat

Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation

Nat. Med20071311731175

10.1038/nm1651

17828272

Ransohoff

R.M.

Immunology: In the beginning

Nature20094624142

10.1038/462041a

19890316

Tesmer

L.A.

Lundy

S.K.

Sarkar

Fox

D.A.

Th17 cells in human disease

Immunol. Rev200822387113

10.1111/j.1600-065X.2008.00628.x

18613831

Hofstetter

H.H.

Ibrahim

S.M.

Koczan

Kruse

Weishaupt

Toyka

K.V.

Gold

Therapeutic efficacy of IL-17 neutralization in murine experimental autoimmune encephalomyelitis

Cell Immunol2005237123130

10.1016/j.cellimm.2005.11.002

16386239

Komiyama

Nakae

Matsuki

Nambu

Ishigame

Kakuta

Sudo

Iwakura

IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis

J. Immunol2006177566573

16785554

Haak

Croxford

A.L.

Kreymborg

Heppner

F.L.

Pouly

Becher

Waisman

IL-17A and IL-17F do not contribute vitally to autoimmune neuro-inflammation in mice

J. Clin. Invest20091196169

19075395

Nowak

E.C.

Weaver

C.T.

Turner

Begum-Haque

Becher

Schreiner

Coyle

A.J.

Kasper

L.H.

Noelle

R.J.

IL-9 as a mediator of Th17-driven inflammatory disease

J. Exp. Med200920616531660

10.1084/jem.20090246

19596803

Sutton

Brereton

Keogh

Mills

K.H.

Lavelle

E.C.

A crucial role for interleukin (IL)-1 in the induction of IL-17-producing T cells that mediate autoimmune encephalomyelitis

J. Exp. Med200620316851691

10.1084/jem.20060285

16818675

Dardalhon

Awasthi

Kwon

Galileos

Gao

Sobel

R.A.

Mitsdoerffer

Strom

T.B.

Elyaman

I.C.

IL-4 inhibits TGF-β-induced Foxp3+ T cells and, together with TGF-β, generates IL-9+ IL-10+ Foxp3(−) effector T cells

Nat. Immunol2008913471355

10.1038/ni.1677

18997793

Veldhoen

Uyttenhove

van Snick

Helmby

Westendorf

Buer

Martin

Wilhelm

Stockinger

Transforming growth factor-β ‘reprograms’ the differentiation of T helper 2 cells and promotes an interleukin 9-producing subset

Nat. Immunol2008913411346

10.1038/ni.1659

18931678

Soroosh

Doherty

T.A.

Th9 and allergic disease

Immunology2009127450458

10.1111/j.1365-2567.2009.03114.x

19604299

Wucherpfennig

K.W.

Newcombe

Keddy

Cuzner

M.L.

Hafler

D.A.

Gamma delta T-cell receptor repertoire in acute multiple sclerosis lesions

Proc. Natl. Acad. Sci. USA19928945884592

10.1073/pnas.89.10.4588

1374907

Shimonkevitz

Colburn

Burnham

J.A.

Murray

R.S.

Kotzin

B.L.

Clonal expansions of activated gamma/delta T cells in recent-onset multiple sclerosis

Proc. Natl. Acad. Sci. USA199390923927

10.1073/pnas.90.3.923

8430106

Lockhart

Green

A.M.

Flynn

J.L.

IL-17 production is dominated by γδ T cells rather than CD4 T cells during Mycobacterium tuberculosis infection

J. Immunol200617746624669

16982905

Shibata

Yamada

Hara

Kishihara

Yoshikai

Resident Vδ1+ γδ T cells control early infiltration of neutrophils after Escherichia coli infection via IL-17 production

J. Immunol200717844664472

17372004

Sutton

C.E.

Lalor

S.J.

Sweeney

C.M.

Brereton

C.F.

Lavelle

E.C.

Mills

K.H.

Interleukin-1 and IL-23 induce innate IL-17 production from γδ T cells, amplifying Th17 responses and autoimmunity

Immunity200931331341

10.1016/j.immuni.2009.08.001

19682929

Kobayashi

Kawai

Ito

Honda

Sobue

Yoshikai

Aggravation of murine experimental allergic encephalomyelitis by administration of T-cell receptor γδ-specific antibody

J. Neuroimmunol199773169174

10.1016/S0165-5728(96)00187-7

9058773

Ponomarev

E.D.

Dittel

B.N.

γδ T cells regulate the extent and duration of inflammation in the central nervous system by a Fas ligand-dependent mechanism

J. Immunol200517446784687

15814692

Ponomarev

E.D.

Novikova

Yassai

Szczepanik

Gorski

Dittel

B.N.

γδ T cell regulation of IFN-γ production by central nervous system-infiltrating encephalitogenic T cells: Correlation with recovery from experimental autoimmune encephalomyelitis

J. Immunol200417315871595

15265886

Rajan

A.J.

Gao

Y.L.

Raine

C.S.

Brosnan

C.F.

A pathogenic role for gamma delta T cells in relapsing-remitting experimental allergic encephalomyelitis in the SJL mouse

J. Immunol1996157941949

8752949

Rajan

A.J.

Klein

J.D.

Brosnan

C.F.

The effect of γδ T cell depletion on cytokine gene expression in experimental allergic encephalomyelitis

J. Immunol199816059555962

9637509

Spahn

T.W.

Issazadah

Salvin

A.J.

Weiner

H.L.

Decreased severity of myelin oligodendrocyte glycoprotein peptide 33–35-induced experimental autoimmune encephalomyelitis in mice with a disrupted TCR δ chain gene

Eur. J. Immunol19992940604071

10.1002/(SICI)1521-4141(199912)29:12<4060::AID-IMMU4060>3.0.CO;2-S

10602017

Odyniec

Szczepanik

Mycko

M.P.

Stasiolek

Raine

C.S.

Selmaj

K.W.

γδ T cells enhance the expression of experimental autoimmune encephalomyelitis by promoting antigen presentation and IL-12 production

J. Immunol2004173682694

15210832

Cardona

A.E.

Teale

J.M.

γ/δ T cell-deficient mice exhibit reduced disease severity and decreased inflammatory response in the brain in murine neurocysticercosis

J. Immunol200216931633171

12218134

Hori

Sakaguchi

Foxp3: A critical regulator of the development and function of regulatory T cells

Microbes Infect20046745751

10.1016/j.micinf.2004.02.020

15207821

Fontenot

J.D.

Gavin

M.A.

Rudensky

A.Y.

Foxp3 programs the development and function of CD4+CD25+ regulatory T cells

Nat. Immunol20034330336

12612578

Sakaguchi

Asano

Itoh

Toda

Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases

J. Immunol199515511511164

7636184

Roncarolo

M.G.

Gregori

Battaglia

Bacchetta

Fleischhauer

Levings

M.K.

Interleukin-10-secreting type 1 regulatory T cells in rodents and humans

Immunol. Rev20062122850

10.1111/j.0105-2896.2006.00420.x

16903904

Martinez-Forero

Garcia-Munoz

Martinez-Pasamar

Inoges

Lopez-Diaz de Cerio

Palacios

Sepulcre

Moreno

Gonzalez

Fernandez-Diez

IL-10 suppressor activity and ex vivo Tr1 cell function are impaired in multiple sclerosis

Eur. J. Immunol200838576586

10.1002/eji.200737271

18200504

Astier

A.L.

Meiffren

Freeman

Hafler

D.A.

Alterations in CD46-mediated Tr1 regulatory T cells in patients with multiple sclerosis

J. Clin. Invest200611632523257

10.1172/JCI29251

17099776

100

Venken

Hellings

Thewissen

Somers

Hensen

Rummens

J.L.

Medaer

Hupperts

Stinissen

Compromised CD4+ CD25(high) regulatory T-cell function in patients with relapsing-remitting multiple sclerosis is correlated with a reduced frequency of FOXP3-positive cells and reduced FOXP3 expression at the single-cell level

Immunology20081237989

10.1111/j.1365-2567.2007.02690.x

17897326

101

Venken

Hellings

Hensen

Rummens

J.L.

Medaer

D’Hooghe

M.B.

Dubois

Raus

Stinissen

Secondary progressive in contrast to relapsing-remitting multiple sclerosis patients show a normal CD4+CD25+ regulatory T-cell function and FOXP3 expression

J. Neurosci. Res20068314321446

10.1002/jnr.20852

16583400

102

Lafaille

J.J.

Nagashima

Katsuki

Tonegawa

High incidence of spontaneous autoimmune encephalomyelitis in immunodeficient anti-myelin basic protein T cell receptor transgenic mice

Cell199478399408

10.1016/0092-8674(94)90419-7

7520367

103

Olivares-Villagomez

Wang

Lafaille

J.J.

Regulatory CD4(+) T cells expressing endogenous T cell receptor chains protect myelin basic protein-specific transgenic mice from spontaneous autoimmune encephalomyelitis

J. Exp. Med199818818831894

10.1084/jem.188.10.1883

9815266

104

Kohm

A.P.

Carpentier

P.A.

Anger

H.A.

Miller

S.D.

Cutting edge: CD4+CD25+ regulatory T cells suppress antigen-specific autoreactive immune responses and central nervous system inflammation during active experimental autoimmune encephalomyelitis

J. Immunol200216947124716

12391178

105

Friese

M.A.

Fugger

Pathogenic CD8(+) T cells in multiple sclerosis

Ann. Neurol200966132141

10.1002/ana.21744

19743458

106

Weiss

H.A.

Millward

J.M.

Owens

CD8+ T cells in inflammatory demyelinating disease

J. Neuroimmunol20071917985

10.1016/j.jneuroim.2007.09.011

17920696

107

Najafian

Chitnis

Salama

A.D.

Zhu

Benou

Yuan

Clarkson

M.R.

Sayegh

M.H.

Khoury

S.J.

Regulatory functions of CD8+CD28- T cells in an autoimmune disease model

J. Clin. Invest200311210371048

14523041

108

Lee

Y.H.

Ishida

Rifa’i

Shi

Isobe

Suzuki

Essential role of CD8+CD122+ regulatory T cells in the recovery from experimental autoimmune encephalomyelitis

J. Immunol2008180825832

18178821

109

Liu

Tugulea

Cortesini

Suciu-Foca

Specific suppression of T helper alloreactivity by allo-MHC class I-restricted CD8+CD28- T cells

Int. Immunol199810775783

10.1093/intimm/10.6.775

9678758

110

Ciubotariu

Colovai

A.I.

Pennesi

Liu

Smith

Berlocco

Cortesini

Suciu-Foca

Specific suppression of human CD4+ Th cell responses to pig MHC antigens by CD8+CD28- regulatory T cells

J. Immunol199816151935202

9820490

111

Jiang

Tugulea

Pennesi

Liu

Mulder

Lederman

Harris

Cortesini

Suciu-Foca

Induction of MHC-class I restricted human suppressor T cells by peptide priming in vitro

Hum. Immunol199859690699

10.1016/S0198-8859(98)00073-1

9796737

112

Liu

Jiang

Cortesini

Lederman

Suciu-Foca

T suppressor lymphocytes inhibit NF-κB-mediated transcription of CD86 gene in APC

J. Immunol199916363866392

10586028

113

Colovai

A.I.

Liu

Ciubotariu

Lederman

Cortesini

Suciu-Foca

Induction of xenoreactive CD4+ T-cell anergy by suppressor CD8+CD28- T cells

Transplantation20006913041310

10.1097/00007890-200004150-00016

10798745

114

Rifa’i

Kawamoto

Nakashima

Suzuki

Essential roles of CD8+CD122+ regulatory T cells in the maintenance of T cell homeostasis

J. Exp. Med200420011231134

10.1084/jem.20040395

15520244

115

Endharti

A.T.

Rifa

I.M.

Shi

Fukuoka

Nakahara

Kawamoto

Takeda

Isobe

Suzuki

Cutting edge: CD8+CD122+ regulatory T cells produce IL-10 to suppress IFN-γ production and proliferation of CD8+ T cells

J. Immunol200517570937097

16301610

116

Linker

R.A.

Rott

Hofstetter

H.H.

Hanke

Toyka

K.V.

Gold

EAE in beta-2 microglobulin-deficient mice: Axonal damage is not dependent on MHC-I restricted immune responses

Neurobiol. Dis200519218228

10.1016/j.nbd.2004.12.017

15837577

117

Jiang

Ware

Stall

Flaherty

Chess

Pernis

Murine CD8+ T cells that specifically delete autologous CD4+ T cells expressing Vβ8 TCR: A role of the Qa-1 molecule

Immunity19952185194

10.1016/S1074-7613(95)80079-4

7895175

118

Jiang

Braunstein

N.S.

Winchester

Chess

CD8+ T cells control the TH phenotype of MBP-reactive CD4+ T cells in EAE mice

Proc. Natl. Acad. Sci. USA20019863016306

10.1073/pnas.101123098

11353822

119

Jiang

Curran

Ruiz-Vazquez

Liang

Winchester

Chess

Regulatory CD8+ T cells fine-tune the myelin basic protein-reactive T cell receptor Vβ repertoire during experimental autoimmune encephalomyelitis

Proc. Natl. Acad. Sci. USA200310083788383

10.1073/pnas.1432871100

12824465

120

Ikizawa

Sanchirico

M.E.

Shinohara

M.L.

Cantor

Analysis of regulatory CD8 T cells in Qa-1-deficient mice

Nat. Immunol20045516523

10.1038/ni1063

15098030

121

Chen

M.L.

Yan

B.S.

Kozoriz

Weiner

H.L.

Novel CD8+ Treg suppress EAE by TGF-β- and IFN-γ-dependent mechanisms

Eur. J. Immunol20093934233435

10.1002/eji.200939441

19768696

122

Lucchinetti

Bruck

Parisi

Scheithauer

Rodriguez

Lassmann

Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelination

Ann. Neurol200047707717

10.1002/1531-8249(200006)47:6<707::AID-ANA3>3.0.CO;2-Q

10852536

123

Breij

E.C.

Brink

B.P.

Veerhuis

van den Berg

Vloet

Yan

Dijkstra

C.D.

van der Valk

Homogeneity of active demyelinating lesions in established multiple sclerosis

Ann. Neurol2008631625

10.1002/ana.21311

18232012

124

Reindl

Linington

Brehm

Egg

Dilitz

Deisenhammer

Poewe

Berger

Antibodies against the myelin oligodendrocyte glycoprotein and the myelin basic protein in multiple sclerosis and other neurological diseases: A comparative study

Brain199912220472056

10.1093/brain/122.11.2047

10545390

125

Van der Goes

Kortekaas

Hoekstra

Dijkstra

C.D.

Amor

The role of anti-myelin (auto)-antibodies in the phagocytosis of myelin by macrophages

J. Neuroimmunol19991016167

10.1016/S0165-5728(99)00133-2

10580814

126

Menon

K.K.

Piddlesden

S.J.

Bernard

C.C.

Demyelinating antibodies to myelin oligodendrocyte glycoprotein and galactocerebroside induce degradation of myelin basic protein in isolated human myelin

J. Neurochem199769214222

9202313

127

Link

Baig

Jiang

Y.P.

Olsson

Hojeberg

Kostulas

Olsson

B cells and antibodies in MS

Res. Immunol1989140219226Discussion 245–218

10.1016/0923-2494(89)90091-6

2662285

128

Lalive

P.H.

Autoantibodies in inflammatory demyelinating diseases of the central nervous system

Swiss Med. Wkly2008138692707

18951202

129

Vyshkina

Kalman

Autoantibodies and neurodegeneration in multiple sclerosis

Lab. Invest200888796807

10.1038/labinvest.2008.53

18521063

130

Hauser

S.L.

Waubant

Arnold

D.L.

Vollmer

Antel

Fox

R.J.

Bar-Or

Panzara

Sarkar

Agarwal

B-cell depletion with rituximab in relapsing-remitting multiple sclerosis

N. Engl. J. Med2008358676688

10.1056/NEJMoa0706383

18272891

131

Harp

C.T.

Lovett-Racke

A.E.

Racke

M.K.

Frohman

E.M.

Monson

N.L.

Impact of myelin-specific antigen presenting B cells on T cell activation in multiple sclerosis

Clin. Immunol2008128382391

10.1016/j.clim.2008.05.002

18599355

132

Correale

Farez

Helminth antigens modulate immune responses in cells from multiple sclerosis patients through TLR2-dependent mechanisms

J. Immunol200918359996012

10.4049/jimmunol.0900897

19812189

133

Steinman

R.M.

Banchereau

Taking dendritic cells into medicine

Nature2007449419426

10.1038/nature06175

17898760

134

Zozulya

A.L.

Clarkson

B.D.

Ortler

Fabry

Wiendl

The role of dendritic cells in CNS autoimmunity

J. Mol. Med. (Berl)201088535544

10.1007/s00109-010-0607-4

135

Menges

Rossner

Voigtlander

Schindler

Kukutsch

N.A.

Bogdan

Erb

Schuler

Lutz

M.B.

Repetitive injections of dendritic cells matured with tumor necrosis factor α induce antigen-specific protection of mice from autoimmunity

J. Exp. Med20021951521

10.1084/jem.20011341

11781361

136

Serafini

Rosicarelli

Magliozzi

Stigliano

Capello

Mancardi

G.L.

Aloisi

Dendritic cells in multiple sclerosis lesions: Maturation stage, myelin uptake, and interaction with proliferating T cells

J. Neuropathol. Exp. Neurol200665124141

10.1097/01.jnen.0000199572.96472.1c

16462204

137

Karni

Abraham

Monsonego

Cai

Freeman

G.J.

Hafler

Khoury

S.J.

Weiner

H.L.

Innate immunity in multiple sclerosis: Myeloid dendritic cells in secondary progressive multiple sclerosis are activated and drive a proinflammatory immune response

J. Immunol200617741964202

16951385

138

Fabriek

B.O.

van Haastert

E.S.

Galea

Polfliet

M.M.

Dopp

E.D.

van Den Heuvel

M.M.

van Den Berg

T.K.

de Groot

C.J.

van Der Valk

Dijkstra

C.D.

CD163-positive perivascular macrophages in the human CNS express molecules for antigen recognition and presentation

Glia200551297305

10.1002/glia.20208

15846794

139

Van Zwam

Huizinga

Melief

M.J.

Wierenga-Wolf

A.F.

van Meurs

Voerman

J.S.

Biber

K.P.

Boddeke

H.W.

Hopken

U.E.

Meisel

Brain antigens in functionally distinct antigen-presenting cell populations in cervical lymph nodes in MS and EAE

J. Mol. Med. (Berl)200987273286

10.1007/s00109-008-0421-4

140

Reubinoff

B.E.

Pera

M.F.

Fong

C.Y.

Trounson

Bongso

Embryonic stem cell lines from human blastocysts: Somatic differentiation in vitro

Nat. Biotechnol200018399404

10.1038/74447

10748519

141

Thomson

J.A.

Itskovitz-Eldor

Shapiro

S.S.

Waknitz

M.A.

Swiergiel

J.J.

Marshall

V.S.

Jones

J.M.

Embryonic stem cell lines derived from human blastocysts

Science199828211451147

10.1126/science.282.5391.1145

9804556

142

Kehat

Kenyagin-Karsenti

Snir

Segev

Amit

Gepstein

Livne

Binah

Itskovitz-Eldor

Gepstein

Human embryonic stem cells can differentiate into myocytes with structural and functional properties of cardiomyocytes

J. Clin. Invest2001108407414

11489934

143

Lavon

Benvenisty

Differentiation and genetic manipulation of human embryonic stem cells and the analysis of the cardiovascular system

Trends Cardiovasc. Med2003134752

10.1016/S1050-1738(02)00199-8

12586438

144

Augello

Kurth

T.B.

de Bari

Mesenchymal stem cells: A perspective from in vitro cultures to in vivo migration and niches

Eur. Cell Mater201020121133

21249629

145

Krampera

Pizzolo

Aprili

Franchini

Mesenchymal stem cells for bone, cartilage, tendon and skeletal muscle repair

Bone200639678683

10.1016/j.bone.2006.04.020

16765663

146

Zhang

Jiang

Mao

Human-placenta-derived mesenchymal stem cells inhibit proliferation and function of allogeneic immune cells

Cell Tissue Res2007330437446

10.1007/s00441-007-0504-5

17899199

147

Zhang

Mitsuru

Igura

Takahashi

Ichinose

Yamaguchi

Takahashi

T.A.

Mesenchymal progenitor cells derived from chorionic villi of human placenta for cartilage tissue engineering

Biochem. Biophys. Res. Commun2006340944952

10.1016/j.bbrc.2005.12.091

16403457

148

Chang

C.J.

Yen

M.L.

Chen

Y.C.

Chien

C.C.

Huang

H.I.

Bai

C.H.

Yen

B.L.

Placenta-derived multipotent cells exhibit immunosuppressive properties that are enhanced in the presence of interferon-γ

Stem. Cells20062424662477

10.1634/stemcells.2006-0071

17071860

149

Jones

B.J.

Brooke

Atkinson

McTaggart

S.J.

Immunosuppression by placental indoleamine 2,3-dioxygenase: A role for mesenchymal stem cells

Placenta20072811741181

10.1016/j.placenta.2007.07.001

17714779

150

Brooke

Tong

Levesque

J.P.

Atkinson

Molecular trafficking mechanisms of multipotent mesenchymal stem cells derived from human bone marrow and placenta

Stem. Cells Dev200817929940

10.1089/scd.2007.0156

18564033

151

Lee

M.Y.

Huang

J.P.

Chen

Y.Y.

Aplin

J.D.

Y.H.

Chen

C.Y.

Chen

P.C.

Chen

C.P.

Angiogenesis in differentiated placental multipotent mesenchymal stromal cells is dependent on integrin α₅β₁

PLoS One20094

10.1371/journal.pone.0006913

152

Chen

D.M.

Zhang

The differentiation of human placenta-derived mesenchymal stem cells into dopaminergic cells in vitro

Cell Mol. Biol. Lett200914528536

10.2478/s11658-009-0015-3

19412574

153

Zhang

X.A.

Wang

Meng

C.L.

Chan

C.Y.

Yew

D.T.

Tsang

K.S.

Tsai

S.N.

Comparative proteomic analysis of mesenchymal stem cells derived from human bone marrow, umbilical cord, and placenta: Implication in the migration

Proteomics200992030

10.1002/pmic.200701195

19116983

154

Hiwase

S.D.

Dyson

P.G.

L.B.

Lewis

I.D.

Cotransplantation of placental mesenchymal stromal cells enhances single and double cord blood engraftment in nonobese diabetic/severe combined immune deficient mice

Stem. Cells20092722932300

10.1002/stem.157

19544531

155

Semenov

O.V.

Koestenbauer

Riegel

Zech

Zimmermann

Zisch

A.H.

Malek

Multipotent mesenchymal stem cells from human placenta: Critical parameters for isolation and maintenance of stemness after isolation

Am. J. Obstet. Gynecol2010202193.e1193.e13

10.1016/j.ajog.2009.10.869

156

Portmann-Lanz

C.B.

Schoeberlein

Huber

Sager

Malek

Holzgreve

Surbek

D.V.

Placental mesenchymal stem cells as potential autologous graft for pre- and perinatal neuroregeneration

Am. J. Obstet. Gynecol2006194664673

10.1016/j.ajog.2006.01.101

16522395

157

Hwang

J.H.

Shim

S.S.

Seok

O.S.

Lee

H.Y.

Woo

S.K.

Kim

B.H.

Song

H.R.

Lee

J.K.

Park

Y.K.

Comparison of cytokine expression in mesenchymal stem cells from human placenta, cord blood, and bone marrow

J. Korean Med. Sci200924547554

10.3346/jkms.2009.24.4.547

19654931

158

Ilancheran

Michalska

Peh

Wallace

E.M.

Pera

Manuelpillai

Stem cells derived from human fetal membranes display multilineage differentiation potential

Biol. Reprod200777577588

10.1095/biolreprod.106.055244

17494917

159

Deuse

Stubbendorff

Tang-Quan

Phillips

Kay

M.A.

Eiermann

Phan

T.T.

Volk

H.D.

Reichenspurner

Robbins

R.C.

Immunogenicity and immunomodulatory properties of umbilical cord lining mesenchymal stem cells

Cell Transplant201120655667

10.3727/096368910X536473

21054940

160

In’t Anker

P.S.

Scherjon

S.A.

Kleijburg-van der Keur

Noort

W.A.

Claas

F.H.

Willemze

Fibbe

W.E.

Kanhai

H.H.

Amniotic fluid as a novel source of mesenchymal stem cells for therapeutic transplantation

Blood200310215481549

10.1182/blood-2003-04-1291

12900350

161

Tomic

Djokic

Vasilijic

Vucevic

Todorovic

Supic

Colic

Immunomodulatory properties of mesenchymal stem cells derived from dental pulp and dental follicle are susceptible to activation by toll-like receptor agonists

Stem. Cells Dev201120695708

10.1089/scd.2010.0145

20731536

162

Bartholomew

Sturgeon

Siatskas

Ferrer

McIntosh

Patil

Hardy

Devine

Ucker

Deans

Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo

Exp. Hematol2002304248

10.1016/S0301-472X(01)00769-X

11823036

163

Djouad

Bony

Haupl

Uze

Lahlou

Louis-Plence

Apparailly

Canovas

Reme

Sany

Transcriptional profiles discriminate bone marrow-derived and synovium-derived mesenchymal stem cells

Arthritis Res. Ther20057R1304R1315

10.1186/ar1827

16277684

164

Tse

W.T.

Pendleton

J.D.

Beyer

W.M.

Egalka

M.C.

Guinan

E.C.

Suppression of allogeneic T-cell proliferation by human marrow stromal cells: Implications in transplantation

Transplantation200375389397

10.1097/01.TP.0000045055.63901.A9

12589164

165

Bocelli-Tyndall

Bracci

Schaeren

Feder-Mengus

Barbero

Tyndall

Spagnoli

G.C.

Human bone marrow mesenchymal stem cells and chondrocytes promote and/or suppress the in vitro proliferation of lymphocytes stimulated by interleukins 2, 7 and 15

Ann. Rheum. Dis20096813521359

10.1136/ard.2008.094003

18647856

166

Schurgers

Kelchtermans

Mitera

Geboes

Matthys

Discrepancy between the in vitro and in vivo effects of murine mesenchymal stem cells on T-cell proliferation and collagen-induced arthritis

Arthritis Res. Ther201012

10.1186/ar2939

167

Chen

C.P.

Liu

S.H.

Huang

J.P.

Aplin

J.D.

Y.H.

Chen

P.C.

C.S.

C.C.

Lee

M.Y.

Chen

C.Y.

Engraftment potential of human placenta-derived mesenchymal stem cells after in utero transplantation in rats

Hum. Reprod200924154165

18845668

168

Chang

Y.J.

Hwang

S.M.

Tseng

C.P.

Cheng

F.C.

Huang

S.H.

Hsu

L.F.

Hsu

L.W.

Tsai

M.S.

Isolation of mesenchymal stem cells with neurogenic potential from the mesoderm of the amniotic membrane

Cells Tissues Organs201019293105

10.1159/000295774

20215735

169

Bailo

Soncini

Vertua

Signoroni

P.B.

Sanzone

Lombardi

Arienti

Calamani

Zatti

Paul

Engraftment potential of human amnion and chorion cells derived from term placenta

Transplantation20047814391448

10.1097/01.TP.0000144606.84234.49

15599307

170

Wolbank

Peterbauer

Fahrner

Hennerbichler

van Griensven

Stadler

Redl

Gabriel

Dose-dependent immunomodulatory effect of human stem cells from amniotic membrane: A comparison with human mesenchymal stem cells from adipose tissue

Tissue Eng20071311731183

10.1089/ten.2006.0313

17518752

171

Gotherstrom

Ringden

Westgren

Tammik

Le Blanc

Immunomodulatory effects of human foetal liver-derived mesenchymal stem cells

Bone Marrow Transplant200332265272

10.1038/sj.bmt.1704111

12858197

172

Giuliani

Fleury

Vernochet

Ketroussi

Clay

Azzarone

Lataillade

J.J.

Durrbach

Long-lasting inhibitory effects of fetal liver mesenchymal stem cells on T-lymphocyte proliferation

PLoS One20116

10.1371/journal.pone.0019988

173

Zheng

Z.H.

X.Y.

Ding

Jia

J.F.

Zhu

Allogeneic mesenchymal stem cell and mesenchymal stem cell-differentiated chondrocyte suppress the responses of type II collagen-reactive T cells in rheumatoid arthritis

Rheumatology (Oxford)2008472230

10.1093/rheumatology/kem284

174

Petrini

Pacini

Petrini

Fazzi

Trombi

Galimberti

Mesenchymal cells inhibit expansion but not cytotoxicity exerted by gamma-delta T cells

Eur. J. Clin. Invest200939813818

10.1111/j.1365-2362.2009.02171.x

19522834

175

Augello

Tasso

Negrini

S.M.

Amateis

Indiveri

Cancedda

Pennesi

Bone marrow mesenchymal progenitor cells inhibit lymphocyte proliferation by activation of the programmed death 1 pathway

Eur. Immunol20053514821490

10.1002/eji.200425405

176

Xue

Luan

X.Y.

Y.Z.

H.Y.

Zhang

G.B.

G.H.

Zhu

H.T.

Wang

Dong

Geng

Y.J.

The negative co-signaling molecule b7-h4 is expressed by human bone marrow-derived mesenchymal stem cells and mediates its T-cell modulatory activity

Stem. Cells Dev2010192738

10.1089/scd.2009.0076

19788399

177

Glennie

Soeiro

Dyson

P.J.

Lam

E.W.

Dazzi

Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells

Blood200510528212827

10.1182/blood-2004-09-3696

15591115

178

Corcione

Benvenuto

Ferretti

Giunti

Cappiello

Cazzanti

Risso

Gualandi

Mancardi

G.L.

Pistoia

Human mesenchymal stem cells modulate B-cell functions

Blood2006107367372

10.1182/blood-2005-07-2657

16141348

179

Asari

Itakura

Ferreri

Liu

C.P.

Kuroda

Kandeel

Mullen

Mesenchymal stem cells suppress B-cell terminal differentiation

Exp. Hematol200937604615

10.1016/j.exphem.2009.01.005

19375651

180

Angoulvant

Clerc

Benchalal

Galambrun

Farre

Bertrand

Eljaafari

Human mesenchymal stem cells suppress induction of cytotoxic response to alloantigens

Biorheology200441469476

15299278

181

Rasmusson

Ringden

Sundberg

Le Blanc

Mesenchymal stem cells inhibit the formation of cytotoxic T lymphocytes, but not activated cytotoxic T lymphocytes or natural killer cells

Transplantation20037612081213

10.1097/01.TP.0000082540.43730.80

14578755

182

Spaggiari

G.M.

Capobianco

Becchetti

Mingari

M.C.

Moretta

Mesenchymal stem cell-natural killer cell interactions: Evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation

Blood200610714841490

10.1182/blood-2005-07-2775

16239427

183

Poggi

Prevosto

Massaro

A.M.

Negrini

Urbani

Pierri

Saccardi

Gobbi

Zocchi

M.R.

Interaction between human NK cells and bone marrow stromal cells inducesNK cell triggering: Role of NKp30 and NKG2D receptors

J. Immunol200517563526360

16272287

184

Hoogduijn

M.J.

Korevaar

S.S.

Engela

A.U.

Weimar

Baan

C.C.

Immunological aspects of allogeneic and autologous mesenchymal stem cell therapies

Hum. Gene Ther20112215871591

10.1089/hum.2011.039

21732766

185

Crop

M.J.

Korevaar

S.S.

de Kuiper

Ijzermans

J.N.

van Besouw

N.M.

Baan

C.C.

Weimar

Hoogduijn

M.J.

Human mesenchymal stem cells are susceptible to lysis by CD8+ T-cells and NK cells

Cell Transplant2011

10.3727/096368910X564076

186

Gonzalez

M.A.

Gonzalez-Rey

Rico

Buscher

Delgado

Adipose-derived mesenchymal stem cells alleviate experimental colitis by inhibiting inflammatory and autoimmune responses

Gastroenterology2009136978989

10.1053/j.gastro.2008.11.041

19135996

187

Christensen

M.E.

Turner

B.E.

Sinfield

L.J.

Kollar

Cullup

Waterhouse

N.J.

Hart

D.N.

Atkinson

Rice

A.M.

Mesenchymal stromal cells transiently alter the inflammatory milieu post-transplant to delay graft-versus-host disease

Haematologica20109521022110

10.3324/haematol.2010.028910

20801899

188

Aggarwal

Pittenger

M.F.

Human mesenchymal stem cells modulate allogeneic immune cell responses

Blood200510518151822

10.1182/blood-2004-04-1559

15494428

189

Groh

M.E.

Maitra

Szekely

Koc

O.N.

Human mesenchymal stem cells require monocyte-mediated activation to suppress alloreactive T cells

Exp. Hematol200533928934

10.1016/j.exphem.2005.05.002

16038786

190

Djouad

Plence

Bony

Tropel

Apparailly

Sany

Noel

Jorgensen

Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals

Blood200310238373844

10.1182/blood-2003-04-1193

12881305

191

Abumaree

Al Jumah

Pace

R.A.

Kalionis

Immunosuppressive properties of mesenchymal stem cells

Stem. Cell Rev20128375392

10.1007/s12015-011-9312-0

21892603

192

Jiang

X.X.

Zhang

Liu

Zhang

S.X.

X.D.

Mao

Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells

Blood200510541204126

10.1182/blood-2004-02-0586

15692068

193

Zhang

Jiang

Zhang

Liu

Tang

Mao

Human placenta-derived mesenchymal progenitor cells support culture expansion of long-term culture-initiating cells from cord blood CD34+ cells

Exp. Hematol200432657664

10.1016/j.exphem.2004.04.001

15246162

194

Zhang

Ren

Yuan

Zhang

Zhao

R.C.

Shi

Immunosuppressive properties of cloned bone marrow mesenchymal stem cells

Cell Res200717240248

17325691

195

Bian

Guo

Z.K.

Wang

H.X.

Wang

J.S.

Wang

Q.F.

Yang

Y.F.

Xiao

F.J.

C.T.

Wang

L.S.

In vitro and in vivo immunosuppressive characteristics of hepatocyte growth factor-modified murine mesenchymal stem cells

In Vivo2009232127

19368120

196

Cargnoni

Gibelli

Tosini

Signoroni

P.B.

Nassuato

Arienti

Lombardi

Albertini

Wengler

G.S.

Parolini

Transplantation of allogeneic and xenogeneic placenta-derived cells reduces bleomycin-induced lung fibrosis

Cell Transplant200918405422

10.3727/096368909788809857

19622228

197

Devine

S.M.

Bartholomew

A.M.

Mahmud

Nelson

Patil

Hardy

Sturgeon

Hewett

Chung

Stock

Mesenchymal stem cells are capable of homing to the bone marrow of non-human primates following systemic infusion

Exp. Hematol200129244255

10.1016/S0301-472X(00)00635-4

11166464

198

Liu

Huang

Zhu

Meng

Liu

Immunomodulatory effects of mesenchymal stem cells involved in favoring type 2 T cell subsets

Transpl. Immunol2009225561

10.1016/j.trim.2009.08.002

19695330

199

Kopen

G.C.

Prockop

D.J.

Phinney

D.G.

Marrow stromal cells migrate throughout forebrain and cerebellum, and they differentiate into astrocytes after injection into neonatal mouse brains

Proc. Natl. Acad. Sci USA1999961071110716

10.1073/pnas.96.19.10711

10485891

200

Devine

S.M.

Cobbs

Jennings

Bartholomew

Hoffman

Mesenchymal stem cells distribute to a wide range of tissues following systemic infusion into nonhuman primates

Blood200310129993001

10.1182/blood-2002-06-1830

12480709

201

Sanchez-Ramos

Song

Cardozo-Pelaez

Hazzi

Stedeford

Willing

Freeman

T.B.

Saporta

Janssen

Patel

Adult bone marrow stromal cells differentiate into neural cells in vitro

Exp. Neurol2000164247256

10.1006/exnr.2000.7389

10915564

202

Woodbury

Schwarz

E.J.

Prockop

D.J.

Black

I.B.

Adult rat and human bone marrow stromal cells differentiate into neurons

J. Neurosci. Res200061364370

10.1002/1097-4547(20000815)61:4<364::AID-JNR2>3.0.CO;2-C

10931522

203

Woodbury

Reynolds

Black

I.B.

Adult bone marrow stromal stem cells express germline, ectodermal, endodermal, and mesodermal genes prior to neurogenesis

J. Neurosci. Res200269908917

10.1002/jnr.10365

12205683

204

Azizi

S.A.

Stokes

Augelli

B.J.

DiGirolamo

Prockop

D.J.

Engraftment and migration of human bone marrow stromal cells implanted in the brains of albino rats—similarities to astrocyte grafts

Proc. Natl. Acad. Sci. USA19989539083913

10.1073/pnas.95.7.3908

9520466

205

Chen

Wang

Zhang

Chopp

Therapeutic benefit of intracerebral transplantation of bone marrow stromal cells after cerebral ischemia in rats

J. Neurol. Sci20011894957

10.1016/S0022-510X(01)00557-3

11535233

206

Zhang

Chen

Yang

Katakowski

Chopp

Expression of insulin-like growth factor 1 and receptor in ischemic rats treated with human marrow stromal cells

Brain Res200410301927

10.1016/j.brainres.2004.09.061

15567334

207

Zhao

L.R.

Duan

W.M.

Reyes

Keene

C.D.

Verfaillie

C.M.

Low

W.C.

Human bone marrow stem cells exhibit neural phenotypes and ameliorate neurological deficits after grafting into the ischemic brain of rats

Exp. Neurol20021741120

10.1006/exnr.2001.7853

11869029

208

Munoz-Elias

Marcus

A.J.

Coyne

T.M.

Woodbury

Black

I.B.

Adult bone marrow stromal cells in the embryonic brain: Engraftment, migration, differentiation, and long-term survival

J. Neurosci20042445854595

10.1523/JNEUROSCI.5060-03.2004

15140930

209

Lepski

Jannes

C.E.

Strauss

Marie

S.K.

Nikkhah

Survival and neuronal differentiation of mesenchymal stem cells transplanted into the rodent brain are dependent upon microenvironment

Tissue Eng. Part A20101627692782

10.1089/ten.tea.2009.0686

20402582

210

Park

Kim

Koh

S.E.

Maeng

Lee

W.D.

Lim

Shim

Lee

Y.J.

Dopaminergic differentiation of neural progenitors derived from placental mesenchymal stem cells in the brains of Parkinson’s disease model rats and alleviation of asymmetric rotational behavior

Brain Res20121466158166

10.1016/j.brainres.2012.05.032

22634376

211

Zhang

Chen

Cui

Elias

S.B.

Mitchell

J.B.

Hammill

Vanguri

Chopp

Human bone marrow stromal cell treatment improves neurological functional recovery in EAE mice

Exp. Neurol20051951626

10.1016/j.expneurol.2005.03.018

15904921

212

Zhang

Cui

Chen

Noffsinger

Elias

S.B.

Chopp

Bone marrow stromal cells reduce axonal loss in experimental autoimmune encephalomyelitis mice

J. Neurosci. Res200684587595

10.1002/jnr.20962

16773650

213

Liu

X.J.

Zhang

J.F.

Sun

Peng

H.S.

Kong

Q.F.

Bai

S.S.

Liu

Y.M.

Wang

G.Y.

Wang

J.H.

H.L.

Reciprocal effect of mesenchymal stem cell on experimental autoimmune encephalomyelitis is mediated by transforming growth factor-beta and interleukin-6

Clin. Exp. Immunol20091583744

10.1111/j.1365-2249.2009.03995.x

19737229

214

Peron

J.P.

Jazedje

Brandao

W.N.

Perin

P.M.

Maluf

Evangelista

L.P.

Halpern

Nisenbaum

M.G.

Czeresnia

C.E.

Zatz

Human endometrial-derived mesenchymal stem cells suppress inflammation in the central nervous system of EAE mice

Stem. Cell Rev2011

10.1007/s12015-011-9338-3

215

Barhum

Gai-Castro

Bahat-Stromza

Barzilay

Melamed

Offen

Intracerebroventricular transplantation of human mesenchymal stem cells induced to secrete neurotrophic factors attenuates clinical symptoms in a mouse model of multiple sclerosis

J. Mol. Neurosci201041129137

10.1007/s12031-009-9302-8

19902385

216

Gordon

Pavlovska

Uney

J.B.

Wraith

D.C.

Scolding

N.J.

Human mesenchymal stem cells infiltrate the spinal cord, reduce demyelination, and localize to white matter lesions in experimental autoimmune encephalomyelitis

J. Neuropathol. Exp. Neurol20106910871095

10.1097/NEN.0b013e3181f97392

20940628

217

Fisher-Shoval

Barhum

Sadan

Yust-Katz

Ben-Zur

Lev

Benkler

Hod

Melamed

Offen

Transplantation of placenta-derived mesenchymal stem cells in the EAE mouse model of MS

J. Mol. Neurosci2012

10.1007/s12031-012-9805-6

218

Bai

Lennon

D.P.

Caplan

A.I.

Dechant

Hecker

Kranso

Zaremba

Miller

R.H.

Hepatocyte growth factor mediates mesenchymal stem cell-induced recovery in multiple sclerosis models

Nat. Neurosci2012

10.1007/s12031-012-9805-6

219

Neuhuber

Timothy Himes

Shumsky

J.S.

Gallo

Fischer

Axon growth and recovery of function supported by human bone marrow stromal cells in the injured spinal cord exhibit donor variations

Brain Res200510357385

10.1016/j.brainres.2004.11.055

15713279

220

Rivera

F.J.

Couillard-Despres

Pedre

Ploetz

Caioni

Lois

Bogdahn

Aigner

Mesenchymal stem cells instruct oligodendrogenic fate decision on adult neural stem cells

Stem. Cells20062422092219

10.1634/stemcells.2005-0614

16763198

221

Rivera

F.J.

Siebzehnrubl

F.A.

Kandasamy

Couillard-Despres

Caioni

Poehler

A.M.

Berninger

Sandner

Bogdahn

Goetz

Mesenchymal stem cells promote oligodendroglial differentiation in hippocampal slice cultures

Cell Physiol. Biochem200924317324

10.1159/000233256

19710546

222

Phinney

D.G.

Prockop

D.J.

Concise review: Mesenchymal stem/multipotent stromal cells: The state of transdifferentiation and modes of tissue repair–current views

Stem. Cells20072528962902

10.1634/stemcells.2007-0637

17901396

223

Mendez-Ferrer

Michurina

T.V.

Ferraro

Mazloom

A.R.

Macarthur

B.D.

Lira

S.A.

Scadden

D.T.

Ma’ayan

Enikolopov

G.N.

Frenette

P.S.

Mesenchymal and haematopoietic stem cells form a unique bone marrow niche

Nature2010466829834

10.1038/nature09262

20703299

224

Lee

R.H.

Pulin

A.A.

Seo

M.J.

Kota

D.J.

Ylostalo

Larson

B.L.

Semprun-Prieto

Delafontaine

Prockop

D.J.

Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6

Cell Stem Cell200955463

10.1016/j.stem.2009.05.003

19570514

225

Parekkadan

van Poll

Suganuma

Carter

E.A.

Berthiaume

Tilles

A.W.

Yarmush

M.L.

Mesenchymal stem cell-derived molecules reverse fulminant hepatic failure

PLoS One20072

10.1371/journal.pone.0000941

226

Scuteri

Cassetti

Tredici

Adult mesenchymal stem cells rescue dorsal root ganglia neurons from dying

Brain Res200611167581

10.1016/j.brainres.2006.07.127

16959225

227

Crigler

Robey

R.C.

Asawachaicharn

Gaupp

Phinney

D.G.

Human mesenchymal stem cell subpopulations express a variety of neuro-regulatory molecules and promote neuronal cell survival and neuritogenesis

Exp. Neurol20061985464

10.1016/j.expneurol.2005.10.029

16336965

228

Wilkins

Kemp

Ginty

Hares

Mallam

Scolding

Human bone marrow-derived mesenchymal stem cells secrete brain-derived neurotrophic factor which promotes neuronal survival in vitro

Stem Cell Res.200936370

10.1016/j.scr.2009.02.006

19411199

229

Bai

Caplan

Lennon

Miller

R.H.

Human mesenchymal stem cells signals regulate neural stem cell fate

Neurochem. Res200732353362

10.1007/s11064-006-9212-x

17191131

230

Akiyama

Radtke

Honmou

Kocsis

J.D.

Remyelination of the spinal cord following intravenous delivery of bone marrow cells

Glia200239229236

10.1002/glia.10102

12203389

231

Satake

Lou

Lenke

L.G.

Migration of mesenchymal stem cells through cerebrospinal fluid into injured spinal cord tissue

Spine (Phila Pa 1976)20042919711979

10.1097/01.brs.0000138273.02820.0a

232

Vercelli

Mereuta

O.M.

Garbossa

Muraca

Mareschi

Rustichelli

Ferrero

Mazzini

Madon

Fagioli

Human mesenchymal stem cell transplantation extends survival, improves motor performance and decreases neuroinflammation in mouse model of amyotrophic lateral sclerosis

Neurobiol. Dis200831395405

10.1016/j.nbd.2008.05.016

18586098

233

Chen

Katakowski

Chen

Wang

Gautam

S.C.

Chopp

Intravenous bone marrow stromal cell therapy reduces apoptosis and promotes endogenous cell proliferation after stroke in female rat

J. Neurosci. Res200373778786

10.1002/jnr.10691

12949903

234

Chen

X.G.

Wang

Gautam

S.C.

Y.X.

Katakowski

Zhang

L.J.

Janakiraman

Human marrow stromal cell therapy for stroke in rat: Neurotrophins and functional recovery

Neurology200259514523

10.1212/WNL.59.4.514

12196642

235

Munoz

J.R.

Stoutenger

B.R.

Robinson

A.P.

Spees

J.L.

Prockop

D.J.

Human stem/progenitor cells from bone marrow promote neurogenesis of endogenous neural stem cells in the hippocampus of mice

Proc. Natl. Acad. Sci. USA20051021817118176

10.1073/pnas.0508945102

16330757

236

Ohtaki

Ylostalo

J.H.

Foraker

J.E.

Robinson

A.P.

Reger

R.L.

Shioda

Prockop

D.J.

Stem/progenitor cells from bone marrow decrease neuronal death in global ischemia by modulation of inflammatory/immune responses

Proc. Natl. Acad. Sci. USA20081051463814643

10.1073/pnas.0803670105

18794523

237

Zhou

Zhang

Chi

Teng

Wang

Song

Zhao

Effects of human marrow stromal cells on activation of microglial cells and production of inflammatory factors induced by lipopolysaccharide

Brain Res200912692330

10.1016/j.brainres.2009.02.049

19269277

238

Kim

Y.J.

Park

H.J.

Lee

Bang

O.Y.

Ahn

Y.H.

Joe

Kim

H.O.

Lee

P.H.

Neuroprotective effects of human mesenchymal stem cells on dopaminergic neurons through anti-inflammatory action

Glia2009571323

10.1002/glia.20731

18661552

239

Lanza

Morando

Voci

Canesi

Principato

M.C.

Serpero

L.D.

Mancardi

Uccelli

Vergani

Neuroprotective mesenchymal stem cells are endowed with a potent antioxidant effect in vivo

J. Neurochem200911016741684

10.1111/j.1471-4159.2009.06268.x

19619133

240

Bork

Pfister

Witt

Horn

Korn

A.D.

Wagner

DNA methylation pattern changes upon long-term culture and aging of human mesenchymal stromal cells

Aging Cell201095463

10.1111/j.1474-9726.2009.00535.x

19895632

241

Bonab

M.M.

Alimoghaddam

Talebian

Ghaffari

S.H.

Ghavamzadeh

Nikbin

Aging of mesenchymal stem cell in vitro

BMC Cell Biol.20067

10.1186/1471-2121-7-14

242

Kassem

Marie

P.J.

Senescence-associated intrinsic mechanisms of osteoblast dysfunctions

Aging Cell201110191197

10.1111/j.1474-9726.2011.00669.x

21210937

243

Mareschi

Ferrero

Rustichelli

Aschero

Gammaitoni

Aglietta

Madon

Fagioli

Expansion of mesenchymal stem cells isolated from pediatric and adult donor bone marrow

J. Cell Biochem200697744754

10.1002/jcb.20681

16229018

244

Moerman

E.J.

Teng

Lipschitz

D.A.

Lecka-Czernik

Aging activates adipogenic and suppresses osteogenic programs in mesenchymal marrow stroma/stem cells: The role of PPAR-γ2 transcription factor and TGF-β/BMP signaling pathways

Aging Cell20043379389

10.1111/j.1474-9728.2004.00127.x

15569355

245

Schallmoser

Bartmann

Rohde

Bork

Guelly

Obenauf

A.C.

Reinisch

Horn

A.D.

Strunk

Replicative senescence-associated gene expression changes in mesenchymal stromal cells are similar under different culture conditions

Haematologica201095867874

10.3324/haematol.2009.011692

20053868

246

Stolzing

Scutt

Age-related impairment of mesenchymal progenitor cell function

Aging Cell20065213224

10.1111/j.1474-9726.2006.00213.x

16842494

247

Tokalov

S.V.

Gruener

Schindler

Iagunov

A.S.

Baumann

Abolmaali

N.D.

A number of bone marrow mesenchymal stem cells but neither phenotype nor differentiation capacities changes with age of rats

Mol. Cells200724255260

17978579

248

Wagner

A.D.

Zenke

Different facets of aging in human mesenchymal stem cells

Tissue Eng. Part B Rev201016445453

10.1089/ten.teb.2009.0825

20196648

249

Wilson

Shehadeh

L.A.

Webster

K.A.

Age-related molecular genetic changes of murine bone marrow mesenchymal stem cells

BMC Genomics201011

10.1186/1471-2164-11-229

250

Zhou

Greenberger

J.S.

Epperly

M.W.

Goff

J.P.

Adler

Leboff

M.S.

Glowacki

Age-related intrinsic changes in human bone-marrow-derived mesenchymal stem cells and their differentiation to osteoblasts

Aging Cell20087335343

10.1111/j.1474-9726.2008.00377.x

18248663

251

Bergman

R.J.

Gazit

Kahn

A.J.

Gruber

McDougall

Hahn

T.J.

Age-related changes in osteogenic stem cells in mice

J. Bone Miner. Res199611568577

9157771

Figures Figure 1

The differentiation of naïve T cells into different subtypes of T cells under the influence of cytokines. Interferon-γ (IFN-γ) and IL-12 convert naïve T cells into T helper 1 cells, whereas IL-4 promotes the development of T helper 2 cells. The differentiation of Th17 cells is promoted by IL-1, IL-6 and IL-23, and the differentiation of regulatory T cells requires TGF-β.

Figure 2

Immunomodulatory effects of MSCs on immune cells, including T cells, NK cells, B cells, monocytes and dendritic cells (DCs). MSCs can inhibit the proliferation and the cytotoxic functions of T and NK cells. MSCs can also modulate the functions of B cells. In addition, the differentiation of monocytes into immature DCs is inhibited by MSCs. Moreover, the maturation of DCs and their ability to activate T cells are also affected by MSCs.

Figure 3

Mesenchymal stem cells can induce neuron recovery in multiple sclerosis via a mechanism that stimulates oligodendrogenesis and decreases the numbers of Th1 and Th17 cells and their secretion of inflammatory cytokines while increasing the numbers of Th2 and Treg cells and their secretion of anti-inflammatory cytokines.